ONTOLOGY REPORT - ANNOTATIONS
| Term: | glucose |
|
| Accession: | CHEBI:17234
|
browse the term
|
| Synonyms: | exact_synonym: | gluco-hexose |
| | related_synonym: | C6H12O6; Glc; Glukose |
| | alt_id: | CHEBI:14313; CHEBI:24277; CHEBI:33929; CHEBI:5418 |
| | xref_casrn: | 50-99-7 |
| | xref: | KEGG COMPOUND:50-99-7 "CAS Registry Number"; KEGG COMPOUND:C00293 "KEGG COMPOUND" |
| | xref_mesh: | MESH:D005947 |
|
|
glucose
|
| G |
ABCB7 |
ATP-binding cassette, sub-family B (MDR/TAP), member 7 |
|
decreases expression |
ISO |
X |
74,273,105 |
74,376,132 |
RGD:6480464 |
CTD |
| G |
ABCC1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
16 |
16,043,434 |
16,236,931 |
RGD:6480464 |
CTD |
| G |
ABCC2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
|
multiple interactions |
ISO |
10 |
101,542,463 |
101,611,662 |
RGD:6480464 |
CTD |
| G |
ACACA |
acetyl-CoA carboxylase alpha |
|
multiple interactions |
EXP |
17 |
35,441,927 |
35,766,902 |
RGD:6480464 |
CTD |
| G |
ACACA |
acetyl-CoA carboxylase alpha |
|
decreases phosphorylation |
EXP |
17 |
35,441,927 |
35,766,902 |
RGD:6480464 |
CTD |
| G |
ACACA |
acetyl-CoA carboxylase alpha |
|
increases expression |
ISO |
17 |
35,441,927 |
35,766,902 |
RGD:6480464 |
CTD |
| G |
ACE |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions |
EXP |
17 |
61,554,422 |
61,575,741 |
RGD:6480464 |
CTD |
| G |
ACE |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
increases expression |
EXP |
17 |
61,554,422 |
61,575,741 |
RGD:6480464 |
CTD |
| G |
ACO2 |
aconitase 2, mitochondrial |
|
multiple interactions |
ISO |
22 |
41,865,129 |
41,924,993 |
RGD:6480464 |
CTD |
| G |
ACOT1 |
acyl-CoA thioesterase 1 |
|
increases expression |
ISO |
14 |
74,003,928 |
74,010,498 |
RGD:6480464 |
CTD |
| G |
ACOX2 |
acyl-CoA oxidase 2, branched chain |
|
decreases expression |
ISO |
3 |
58,490,863 |
58,522,929 |
RGD:6480464 |
CTD |
| G |
ACTA2 |
actin, alpha 2, smooth muscle, aorta |
|
multiple interactions |
ISO |
10 |
90,694,831 |
90,751,147 |
RGD:6480464 |
CTD |
| G |
ACTA2 |
actin, alpha 2, smooth muscle, aorta |
|
increases expression |
ISO |
10 |
90,694,831 |
90,751,147 |
RGD:6480464 |
CTD |
| G |
ACTB |
actin, beta |
|
decreases expression |
EXP |
7 |
5,566,779 |
5,570,232 |
RGD:6480464 |
CTD |
| G |
ADAM8 |
ADAM metallopeptidase domain 8 |
|
increases expression |
ISO |
10 |
135,075,920 |
135,090,407 |
RGD:6480464 |
CTD |
| G |
ADAMTS1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
increases expression |
ISO |
21 |
28,208,606 |
28,217,728 |
RGD:6480464 |
CTD |
| G |
ADHFE1 |
alcohol dehydrogenase, iron containing, 1 |
|
decreases expression |
ISO |
8 |
67,344,718 |
67,381,044 |
RGD:6480464 |
CTD |
| G |
ADRA1A |
adrenoceptor alpha 1A |
|
multiple interactions |
ISO |
8 |
26,605,667 |
26,722,922 |
RGD:6480464 |
CTD |
| G |
ADRB2 |
adrenoceptor beta 2, surface |
|
multiple interactions |
ISO |
5 |
148,206,156 |
148,208,197 |
RGD:6480464 |
CTD |
| G |
AFP |
alpha-fetoprotein |
|
increases expression |
ISO |
4 |
74,301,933 |
74,321,492 |
RGD:6480464 |
CTD |
| G |
AGER |
advanced glycosylation end product-specific receptor |
|
increases expression |
EXP |
6 |
32,148,745 |
32,152,099 |
RGD:6480464 |
CTD |
| G |
AGER |
advanced glycosylation end product-specific receptor |
|
multiple interactions |
EXP |
6 |
32,148,745 |
32,152,099 |
RGD:6480464 |
CTD |
| G |
AGER |
advanced glycosylation end product-specific receptor |
|
increases expression |
ISO |
6 |
32,148,745 |
32,152,099 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
affects metabolic processing |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
EXP |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
increases expression |
EXP |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AGTR1 |
angiotensin II receptor, type 1 |
|
multiple interactions |
EXP |
3 |
148,415,658 |
148,460,790 |
RGD:6480464 |
CTD |
| G |
AGTR1 |
angiotensin II receptor, type 1 |
|
increases expression |
EXP |
3 |
148,415,658 |
148,460,790 |
RGD:6480464 |
CTD |
| G |
AHR |
aryl hydrocarbon receptor |
|
increases response to substance |
ISO |
7 |
17,338,276 |
17,385,775 |
RGD:6480464 |
CTD |
| G |
AIFM1 |
apoptosis-inducing factor, mitochondrion-associated, 1 |
|
affects localization |
ISO |
X |
129,263,337 |
129,299,861 |
RGD:6480464 |
CTD |
| G |
AKR1A1 |
aldo-keto reductase family 1, member A1 (aldehyde reductase) |
|
multiple interactions |
ISO |
1 |
46,016,455 |
46,035,723 |
RGD:6480464 |
CTD |
| G |
AKR1A1 |
aldo-keto reductase family 1, member A1 (aldehyde reductase) |
|
decreases expression |
ISO |
1 |
46,016,455 |
46,035,723 |
RGD:6480464 |
CTD |
| G |
AKR1B1 |
aldo-keto reductase family 1, member B1 (aldose reductase) |
|
increases expression |
ISO |
7 |
134,127,107 |
134,143,888 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases expression |
ISO |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
ISO |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases response to substance |
ISO |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases phosphorylation |
EXP |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases phosphorylation |
EXP |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
AKT2 |
v-akt murine thymoma viral oncogene homolog 2 |
|
affects response to substance |
ISO |
19 |
40,736,224 |
40,791,302 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
decreases uptake |
EXP |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
multiple interactions |
EXP |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
multiple interactions |
EXP |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
multiple interactions |
ISO |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALB |
albumin |
|
increases metabolic processing |
EXP |
4 |
74,269,972 |
74,287,129 |
RGD:6480464 |
CTD |
| G |
ALDH1B1 |
aldehyde dehydrogenase 1 family, member B1 |
|
increases expression |
EXP |
9 |
38,392,661 |
38,398,662 |
RGD:6480464 |
CTD |
| G |
ALDH6A1 |
aldehyde dehydrogenase 6 family, member A1 |
|
decreases expression |
ISO |
14 |
74,526,869 |
74,551,196 |
RGD:6480464 |
CTD |
| G |
ALG12 |
ALG12, alpha-1,6-mannosyltransferase |
|
decreases expression |
ISO |
22 |
50,296,852 |
50,312,106 |
RGD:6480464 |
CTD |
| G |
ALOX5 |
arachidonate 5-lipoxygenase |
|
multiple interactions |
ISO |
10 |
45,869,624 |
45,941,567 |
RGD:6480464 |
CTD |
| G |
AMOT |
angiomotin |
|
decreases expression |
ISO |
X |
112,018,105 |
112,084,043 |
RGD:6480464 |
CTD |
| G |
ANGPTL4 |
angiopoietin-like 4 |
|
increases expression |
ISO |
19 |
8,429,011 |
8,439,257 |
RGD:6480464 |
CTD |
| G |
APC |
adenomatous polyposis coli |
|
decreases expression |
ISO |
5 |
112,043,202 |
112,181,936 |
RGD:6480464 |
CTD |
| G |
APOA1 |
apolipoprotein A-I |
|
decreases expression |
ISO |
11 |
116,706,469 |
116,708,338 |
RGD:6480464 |
CTD |
| G |
APOA1 |
apolipoprotein A-I |
|
increases expression |
ISO |
11 |
116,706,469 |
116,708,338 |
RGD:6480464 |
CTD |
| G |
AQP1 |
aquaporin 1 (Colton blood group) |
|
multiple interactions |
ISO |
7 |
30,951,415 |
30,965,131 |
RGD:6480464 |
CTD |
| G |
AQP1 |
aquaporin 1 (Colton blood group) |
|
increases expression |
ISO |
7 |
30,951,415 |
30,965,131 |
RGD:6480464 |
CTD |
| G |
AQP4 |
aquaporin 4 |
|
multiple interactions |
ISO |
18 |
24,432,007 |
24,445,716 |
RGD:6480464 |
CTD |
| G |
AQP4 |
aquaporin 4 |
|
increases expression |
ISO |
18 |
24,432,007 |
24,445,716 |
RGD:6480464 |
CTD |
| G |
ARG2 |
arginase, type II |
|
increases expression |
ISO |
14 |
68,086,579 |
68,118,437 |
RGD:6480464 |
CTD |
| G |
ARL5B |
ADP-ribosylation factor-like 5B |
|
increases expression |
ISO |
10 |
18,948,313 |
18,966,940 |
RGD:6480464 |
CTD |
| G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
|
multiple interactions |
EXP |
1 |
150,782,181 |
150,849,244 |
RGD:6480464 |
CTD |
| G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
|
increases activity |
ISO |
1 |
150,782,181 |
150,849,244 |
RGD:6480464 |
CTD |
| G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
|
multiple interactions |
ISO |
1 |
150,782,181 |
150,849,244 |
RGD:6480464 |
CTD |
| G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
|
affects expression |
EXP |
7 |
97,481,429 |
97,501,854 |
RGD:6480464 |
CTD |
| G |
ATP6AP2 |
ATPase, H+ transporting, lysosomal accessory protein 2 |
|
increases expression |
ISO |
X |
40,440,216 |
40,465,889 |
RGD:6480464 |
CTD |
| G |
ATP6AP2 |
ATPase, H+ transporting, lysosomal accessory protein 2 |
|
multiple interactions |
ISO |
X |
40,440,216 |
40,465,889 |
RGD:6480464 |
CTD |
| G |
AURKA |
aurora kinase A |
|
increases expression |
ISO |
20 |
54,944,445 |
54,967,351 |
RGD:6480464 |
CTD |
| G |
B3GAT3 |
beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) |
|
multiple interactions |
ISO |
11 |
62,382,768 |
62,389,647 |
RGD:6480464 |
CTD |
| G |
B3GAT3 |
beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) |
|
increases expression |
ISO |
11 |
62,382,768 |
62,389,647 |
RGD:6480464 |
CTD |
| G |
B3GAT3 |
beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) |
|
increases expression |
ISO |
11 |
62,382,768 |
62,389,647 |
RGD:6480464 |
CTD |
| G |
B3GAT3 |
beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) |
|
multiple interactions |
ISO |
11 |
62,382,768 |
62,389,647 |
RGD:6480464 |
CTD |
| G |
BAD |
BCL2-associated agonist of cell death |
|
multiple interactions |
ISO |
11 |
64,037,300 |
64,052,176 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BMP2 |
bone morphogenetic protein 2 |
|
multiple interactions |
EXP |
20 |
6,748,745 |
6,760,910 |
RGD:6480464 |
CTD |
| G |
BMP2 |
bone morphogenetic protein 2 |
|
decreases expression |
EXP |
20 |
6,748,745 |
6,760,910 |
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
increases expression |
ISO |
19 |
6,677,846 |
6,720,662 |
RGD:6480464 |
CTD |
| G |
CALR |
calreticulin |
|
decreases expression |
ISO |
19 |
13,049,414 |
13,055,304 |
RGD:6480464 |
CTD |
| G |
CANX |
calnexin |
|
decreases expression |
ISO |
5 |
179,125,930 |
179,158,642 |
RGD:6480464 |
CTD |
| G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
11 |
104,896,235 |
104,905,884 |
RGD:6480464 |
CTD |
| G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
11 |
104,896,235 |
104,905,884 |
RGD:6480464 |
CTD |
| G |
CASP1 |
caspase 1, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
11 |
104,896,235 |
104,905,884 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases cleavage |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
EXP |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
multiple interactions |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
decreases expression |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAV1 |
caveolin 1, caveolae protein, 22kDa |
|
multiple interactions |
EXP |
7 |
116,164,839 |
116,201,239 |
RGD:6480464 |
CTD |
| G |
CAV1 |
caveolin 1, caveolae protein, 22kDa |
|
decreases expression |
EXP |
7 |
116,164,839 |
116,201,239 |
RGD:6480464 |
CTD |
| G |
CBR3 |
carbonyl reductase 3 |
|
increases expression |
ISO |
21 |
37,507,263 |
37,518,860 |
RGD:6480464 |
CTD |
| G |
CBS |
cystathionine-beta-synthase |
|
increases expression |
ISO |
21 |
44,473,301 |
44,496,472 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases secretion |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CCL5 |
chemokine (C-C motif) ligand 5 |
|
increases expression |
ISO |
17 |
34,198,495 |
34,207,377 |
RGD:6480464 |
CTD |
| G |
CCNL1 |
cyclin L1 |
|
increases expression |
ISO |
3 |
156,865,585 |
156,878,482 |
RGD:6480464 |
CTD |
| G |
CD14 |
CD14 molecule |
|
multiple interactions |
EXP |
5 |
140,011,313 |
140,013,286 |
RGD:6480464 |
CTD |
| G |
CD44 |
CD44 molecule (Indian blood group) |
|
increases expression |
ISO |
11 |
35,160,417 |
35,253,949 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
increases expression |
ISO |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CEACAM1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
multiple interactions |
EXP |
19 |
43,011,458 |
43,032,661 |
RGD:6480464 |
CTD |
| G |
CEACAM1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
decreases expression |
EXP |
19 |
43,011,458 |
43,032,661 |
RGD:6480464 |
CTD |
| G |
CEACAM1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
decreases secretion |
EXP |
19 |
43,011,458 |
43,032,661 |
RGD:6480464 |
CTD |
| G |
CHRM2 |
cholinergic receptor, muscarinic 2 |
|
increases expression |
ISO |
7 |
136,553,399 |
136,701,771 |
RGD:6480464 |
CTD |
| G |
CKB |
creatine kinase, brain |
|
multiple interactions |
EXP |
14 |
103,985,995 |
103,989,196 |
RGD:6480464 |
CTD |
| G |
CKB |
creatine kinase, brain |
|
increases activity |
EXP |
14 |
103,985,995 |
103,989,196 |
RGD:6480464 |
CTD |
| G |
CKS2 |
CDC28 protein kinase regulatory subunit 2 |
|
increases expression |
ISO |
9 |
91,926,113 |
91,931,618 |
RGD:6480464 |
CTD |
| G |
CNIH2 |
cornichon homolog 2 (Drosophila) |
|
increases expression |
ISO |
11 |
66,045,672 |
66,051,685 |
RGD:6480464 |
CTD |
| G |
CNR1 |
cannabinoid receptor 1 (brain) |
|
decreases expression |
ISO |
6 |
88,849,583 |
88,875,767 |
RGD:6480464 |
CTD |
| G |
COL1A2 |
collagen, type I, alpha 2 |
|
increases expression |
EXP |
7 |
94,023,873 |
94,060,544 |
RGD:6480464 |
CTD |
| G |
COL1A2 |
collagen, type I, alpha 2 |
|
multiple interactions |
EXP |
7 |
94,023,873 |
94,060,544 |
RGD:6480464 |
CTD |
| G |
COL3A1 |
collagen, type III, alpha 1 |
|
increases expression |
ISO |
2 |
189,839,099 |
189,877,472 |
RGD:6480464 |
CTD |
| G |
COL3A1 |
collagen, type III, alpha 1 |
|
multiple interactions |
ISO |
2 |
189,839,099 |
189,877,472 |
RGD:6480464 |
CTD |
| G |
COL4A1 |
collagen, type IV, alpha 1 |
|
multiple interactions |
ISO |
13 |
110,801,310 |
110,959,496 |
RGD:6480464 |
CTD |
| G |
COL4A1 |
collagen, type IV, alpha 1 |
|
increases expression |
ISO |
13 |
110,801,310 |
110,959,496 |
RGD:6480464 |
CTD |
| G |
CREB1 |
cAMP responsive element binding protein 1 |
|
increases activity |
ISO |
2 |
208,394,616 |
208,470,284 |
RGD:6480464 |
CTD |
| G |
CSRNP1 |
cysteine-serine-rich nuclear protein 1 |
|
increases expression |
ISO |
3 |
39,183,342 |
39,195,102 |
RGD:6480464 |
CTD |
| G |
CTGF |
connective tissue growth factor |
|
increases expression |
EXP |
6 |
132,269,316 |
132,272,518 |
RGD:6480464 |
CTD |
| G |
CTGF |
connective tissue growth factor |
|
multiple interactions |
EXP |
6 |
132,269,316 |
132,272,518 |
RGD:6480464 |
CTD |
| G |
CTGF |
connective tissue growth factor |
|
multiple interactions |
EXP |
6 |
132,269,316 |
132,272,518 |
RGD:6480464 |
CTD |
| G |
CTGF |
connective tissue growth factor |
|
increases expression |
EXP |
6 |
132,269,316 |
132,272,518 |
RGD:6480464 |
CTD |
| G |
CTGF |
connective tissue growth factor |
|
multiple interactions |
ISO |
6 |
132,269,316 |
132,272,518 |
RGD:6480464 |
CTD |
| G |
CTGF |
connective tissue growth factor |
|
increases expression |
ISO |
6 |
132,269,316 |
132,272,518 |
RGD:6480464 |
CTD |
| G |
CTNNB1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
|
decreases expression |
ISO |
3 |
41,240,942 |
41,281,939 |
RGD:6480464 |
CTD |
| G |
CTNNB1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
|
multiple interactions |
ISO |
3 |
41,240,942 |
41,281,939 |
RGD:6480464 |
CTD |
| G |
CTNNB1 |
catenin (cadherin-associated protein), beta 1, 88kDa |
|
decreases expression |
ISO |
3 |
41,240,942 |
41,281,939 |
RGD:6480464 |
CTD |
| G |
CTSB |
cathepsin B |
|
multiple interactions |
EXP |
8 |
11,700,033 |
11,725,646 |
RGD:6480464 |
CTD |
| G |
CTSB |
cathepsin B |
|
increases expression |
ISO |
8 |
11,700,033 |
11,725,646 |
RGD:6480464 |
CTD |
| G |
CX3CL1 |
chemokine (C-X3-C motif) ligand 1 |
|
multiple interactions |
EXP |
16 |
57,406,414 |
57,418,956 |
RGD:6480464 |
CTD |
| G |
CX3CL1 |
chemokine (C-X3-C motif) ligand 1 |
|
increases expression |
EXP |
16 |
57,406,414 |
57,418,956 |
RGD:6480464 |
CTD |
| G |
CXCL1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
ISO |
4 |
74,735,109 |
74,737,019 |
RGD:6480464 |
CTD |
| G |
CXCL10 |
chemokine (C-X-C motif) ligand 10 |
|
increases expression |
ISO |
4 |
76,942,269 |
76,944,689 |
RGD:6480464 |
CTD |
| G |
CXCL2 |
chemokine (C-X-C motif) ligand 2 |
|
increases expression |
ISO |
4 |
74,962,752 |
74,964,997 |
RGD:6480464 |
CTD |
| G |
CXCR4 |
chemokine (C-X-C motif) receptor 4 |
|
multiple interactions |
ISO |
2 |
136,871,919 |
136,875,725 |
RGD:6480464 |
CTD |
| G |
CYBA |
cytochrome b-245, alpha polypeptide |
|
multiple interactions |
ISO |
16 |
88,709,697 |
88,717,492 |
RGD:6480464 |
CTD |
| G |
CYBA |
cytochrome b-245, alpha polypeptide |
|
increases expression |
ISO |
16 |
88,709,697 |
88,717,492 |
RGD:6480464 |
CTD |
| G |
CYBA |
cytochrome b-245, alpha polypeptide |
|
increases expression |
EXP |
16 |
88,709,697 |
88,717,492 |
RGD:6480464 |
CTD |
| G |
CYBA |
cytochrome b-245, alpha polypeptide |
|
multiple interactions |
EXP |
16 |
88,709,697 |
88,717,492 |
RGD:6480464 |
CTD |
| G |
CYBA |
cytochrome b-245, alpha polypeptide |
|
multiple interactions |
EXP |
16 |
88,709,697 |
88,717,492 |
RGD:6480464 |
CTD |
| G |
CYBA |
cytochrome b-245, alpha polypeptide |
|
increases expression |
EXP |
16 |
88,709,697 |
88,717,492 |
RGD:6480464 |
CTD |
| G |
CYBB |
cytochrome b-245, beta polypeptide |
|
multiple interactions |
ISO |
X |
37,639,270 |
37,672,714 |
RGD:6480464 |
CTD |
| G |
CYP11B2 |
cytochrome P450, family 11, subfamily B, polypeptide 2 |
|
decreases expression |
ISO |
8 |
143,991,975 |
143,999,259 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions |
EXP |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
increases expression |
EXP |
15 |
75,011,883 |
75,017,877 |
RGD:6480464 |
CTD |
| G |
CYR61 |
cysteine-rich, angiogenic inducer, 61 |
|
increases expression |
ISO |
1 |
86,046,444 |
86,049,650 |
RGD:6480464 |
CTD |
| G |
DAXX |
death-domain associated protein |
|
affects localization |
EXP |
6 |
33,286,335 |
33,290,793 |
RGD:6480464 |
CTD |
| G |
DAXX |
death-domain associated protein |
|
multiple interactions |
EXP |
6 |
33,286,335 |
33,290,793 |
RGD:6480464 |
CTD |
| G |
DBI |
diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) |
|
increases expression |
ISO |
2 |
120,124,504 |
120,130,122 |
RGD:6480464 |
CTD |
| G |
DDIT3 |
DNA-damage-inducible transcript 3 |
|
decreases expression |
ISO |
12 |
57,910,371 |
57,914,300 |
RGD:6480464 |
CTD |
| G |
DDIT3 |
DNA-damage-inducible transcript 3 |
|
increases expression |
ISO |
12 |
57,910,371 |
57,914,300 |
RGD:6480464 |
CTD |
| G |
DGKD |
diacylglycerol kinase, delta 130kDa |
|
multiple interactions |
EXP |
2 |
234,263,153 |
234,380,743 |
RGD:6480464 |
CTD |
| G |
DGKD |
diacylglycerol kinase, delta 130kDa |
|
affects localization |
EXP |
2 |
234,263,153 |
234,380,743 |
RGD:6480464 |
CTD |
| G |
DGKD |
diacylglycerol kinase, delta 130kDa |
|
affects localization |
ISO |
2 |
234,263,153 |
234,380,743 |
RGD:6480464 |
CTD |
| G |
DNAJB11 |
DnaJ (Hsp40) homolog, subfamily B, member 11 |
|
decreases expression |
ISO |
3 |
186,288,467 |
186,303,589 |
RGD:6480464 |
CTD |
| G |
DNAJC3 |
DnaJ (Hsp40) homolog, subfamily C, member 3 |
|
decreases expression |
ISO |
13 |
96,329,393 |
96,447,243 |
RGD:6480464 |
CTD |
| G |
DUSP1 |
dual specificity phosphatase 1 |
|
increases expression |
ISO |
5 |
172,195,093 |
172,198,203 |
RGD:6480464 |
CTD |
| G |
DUSP2 |
dual specificity phosphatase 2 |
|
increases expression |
ISO |
2 |
96,808,908 |
96,811,179 |
RGD:6480464 |
CTD |
| G |
DUSP6 |
dual specificity phosphatase 6 |
|
increases expression |
ISO |
12 |
89,741,837 |
89,746,296 |
RGD:6480464 |
CTD |
| G |
EDEM1 |
ER degradation enhancer, mannosidase alpha-like 1 |
|
decreases expression |
ISO |
3 |
5,229,359 |
5,261,650 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
increases expression |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
multiple interactions |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
multiple interactions |
ISO |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
multiple interactions |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
increases expression |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
increases expression |
EXP |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN3 |
endothelin 3 |
|
multiple interactions |
ISO |
20 |
57,875,499 |
57,901,047 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
EXP |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGF |
epidermal growth factor |
|
multiple interactions |
EXP |
4 |
110,834,040 |
110,934,118 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
multiple interactions |
EXP |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
increases expression |
EXP |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EGR1 |
early growth response 1 |
|
increases expression |
ISO |
5 |
137,801,181 |
137,805,004 |
RGD:6480464 |
CTD |
| G |
EIF2AK2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
|
multiple interactions |
ISO |
2 |
37,332,281 |
37,384,190 |
RGD:6480464 |
CTD |
| G |
EIF2AK2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
|
increases phosphorylation |
ISO |
2 |
37,332,281 |
37,384,190 |
RGD:6480464 |
CTD |
| G |
EIF2S1 |
eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa |
|
multiple interactions |
ISO |
14 |
67,827,034 |
67,853,233 |
RGD:6480464 |
CTD |
| G |
EIF2S1 |
eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa |
|
increases phosphorylation |
ISO |
14 |
67,827,034 |
67,853,233 |
RGD:6480464 |
CTD |
| G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
multiple interactions |
ISO |
8 |
37,888,020 |
37,917,883 |
RGD:6480464 |
CTD |
| G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
multiple interactions |
ISO |
8 |
37,888,020 |
37,917,883 |
RGD:6480464 |
CTD |
| G |
ELK3 |
ELK3, ETS-domain protein (SRF accessory protein 2) |
|
increases expression |
ISO |
12 |
96,588,207 |
96,661,606 |
RGD:6480464 |
CTD |
| G |
ELOVL6 |
ELOVL fatty acid elongase 6 |
|
increases expression |
ISO |
4 |
110,970,229 |
111,119,820 |
RGD:6480464 |
CTD |
| G |
ELOVL6 |
ELOVL fatty acid elongase 6 |
|
increases expression |
ISO |
4 |
110,970,229 |
111,119,820 |
RGD:6480464 |
CTD |
| G |
ENDOG |
endonuclease G |
|
multiple interactions |
EXP |
9 |
131,580,779 |
131,584,955 |
RGD:6480464 |
CTD |
| G |
ERBB3 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) |
|
multiple interactions |
ISO |
12 |
56,473,809 |
56,497,291 |
RGD:6480464 |
CTD |
| G |
ERO1L |
ERO1-like (S. cerevisiae) |
|
decreases expression |
ISO |
14 |
53,108,605 |
53,162,419 |
RGD:6480464 |
CTD |
| G |
ESR1 |
estrogen receptor 1 |
|
decreases expression |
EXP |
6 |
152,011,631 |
152,424,409 |
RGD:6480464 |
CTD |
| G |
ESR1 |
estrogen receptor 1 |
|
increases expression |
EXP |
6 |
152,011,631 |
152,424,409 |
RGD:6480464 |
CTD |
| G |
ESR2 |
estrogen receptor 2 (ER beta) |
|
decreases expression |
EXP |
14 |
64,693,751 |
64,805,268 |
RGD:6480464 |
CTD |
| G |
ESR2 |
estrogen receptor 2 (ER beta) |
|
increases expression |
EXP |
14 |
64,693,751 |
64,805,268 |
RGD:6480464 |
CTD |
| G |
FABP4 |
fatty acid binding protein 4, adipocyte |
|
multiple interactions |
ISO |
8 |
82,390,732 |
82,395,473 |
RGD:6480464 |
CTD |
| G |
FASN |
fatty acid synthase |
|
increases expression |
ISO |
17 |
80,036,214 |
80,056,106 |
RGD:6480464 |
CTD |
| G |
FGF2 |
fibroblast growth factor 2 (basic) |
|
increases expression |
ISO |
4 |
123,747,863 |
123,819,390 |
RGD:6480464 |
CTD |
| G |
FGF2 |
fibroblast growth factor 2 (basic) |
|
multiple interactions |
ISO |
4 |
123,747,863 |
123,819,390 |
RGD:6480464 |
CTD |
| G |
FGF2 |
fibroblast growth factor 2 (basic) |
|
increases expression |
ISO |
4 |
123,747,863 |
123,819,390 |
RGD:6480464 |
CTD |
| G |
FGF21 |
fibroblast growth factor 21 |
|
affects uptake |
EXP |
19 |
49,259,344 |
49,261,582 |
RGD:6480464 |
CTD |
| G |
FGF21 |
fibroblast growth factor 21 |
|
affects uptake |
ISO |
19 |
49,259,344 |
49,261,582 |
RGD:6480464 |
CTD |
| G |
FGF7 |
fibroblast growth factor 7 |
|
affects transport |
ISO |
15 |
49,715,375 |
49,779,523 |
RGD:6480464 |
CTD |
| G |
FIGF |
c-fos induced growth factor (vascular endothelial growth factor D) |
|
increases expression |
ISO |
X |
15,363,713 |
15,402,535 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases secretion |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
decreases expression |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
decreases expression |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
ISO |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
increases expression |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FOLR1 |
folate receptor 1 (adult) |
|
decreases expression |
EXP |
11 |
71,900,602 |
71,907,367 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
EXP |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOSL1 |
FOS-like antigen 1 |
|
multiple interactions |
EXP |
11 |
65,659,692 |
65,667,997 |
RGD:6480464 |
CTD |
| G |
FOSL1 |
FOS-like antigen 1 |
|
increases expression |
EXP |
11 |
65,659,692 |
65,667,997 |
RGD:6480464 |
CTD |
| G |
FOSL1 |
FOS-like antigen 1 |
|
increases expression |
ISO |
11 |
65,659,692 |
65,667,997 |
RGD:6480464 |
CTD |
| G |
FOSL2 |
FOS-like antigen 2 |
|
increases expression |
ISO |
2 |
28,615,779 |
28,637,516 |
RGD:6480464 |
CTD |
| G |
FOXA2 |
forkhead box A2 |
|
multiple interactions |
ISO |
20 |
22,561,642 |
22,566,101 |
RGD:6480464 |
CTD |
| G |
FOXO1 |
forkhead box O1 |
|
increases abundance |
ISO |
13 |
41,129,801 |
41,240,734 |
RGD:6480464 |
CTD |
| G |
FOXO1 |
forkhead box O1 |
|
multiple interactions |
ISO |
13 |
41,129,801 |
41,240,734 |
RGD:6480464 |
CTD |
| G |
FOXO3 |
forkhead box O3 |
|
multiple interactions |
ISO |
6 |
108,881,026 |
109,005,971 |
RGD:6480464 |
CTD |
| G |
FOXO3 |
forkhead box O3 |
|
increases localization |
ISO |
6 |
108,881,026 |
109,005,971 |
RGD:6480464 |
CTD |
| G |
FRK |
fyn-related kinase |
|
multiple interactions |
ISO |
6 |
116,262,693 |
116,381,921 |
RGD:6480464 |
CTD |
| G |
FTH1 |
ferritin, heavy polypeptide 1 |
|
multiple interactions |
ISO |
11 |
61,731,757 |
61,735,132 |
RGD:6480464 |
CTD |
| G |
FXYD5 |
FXYD domain containing ion transport regulator 5 |
|
increases expression |
ISO |
19 |
35,645,625 |
35,660,788 |
RGD:6480464 |
CTD |
| G |
G6PC |
glucose-6-phosphatase, catalytic subunit |
|
multiple interactions |
EXP |
17 |
41,052,814 |
41,066,450 |
RGD:6480464 |
CTD |
| G |
G6PC |
glucose-6-phosphatase, catalytic subunit |
|
decreases expression |
ISO |
17 |
41,052,814 |
41,066,450 |
RGD:6480464 |
CTD |
| G |
G6PC |
glucose-6-phosphatase, catalytic subunit |
|
increases activity |
ISO |
17 |
41,052,814 |
41,066,450 |
RGD:6480464 |
CTD |
| G |
G6PC |
glucose-6-phosphatase, catalytic subunit |
|
increases expression |
ISO |
17 |
41,052,814 |
41,066,450 |
RGD:6480464 |
CTD |
| G |
G6PC |
glucose-6-phosphatase, catalytic subunit |
|
multiple interactions |
ISO |
17 |
41,052,814 |
41,066,450 |
RGD:6480464 |
CTD |
| G |
G6PC |
glucose-6-phosphatase, catalytic subunit |
|
multiple interactions |
ISO |
17 |
41,052,814 |
41,066,450 |
RGD:6480464 |
CTD |
| G |
G6PC |
glucose-6-phosphatase, catalytic subunit |
|
multiple interactions |
EXP |
17 |
41,052,814 |
41,066,450 |
RGD:6480464 |
CTD |
| G |
GAD1 |
glutamate decarboxylase 1 (brain, 67kDa) |
|
multiple interactions |
ISO |
2 |
171,673,200 |
171,717,661 |
RGD:6480464 |
CTD |
| G |
GAD1 |
glutamate decarboxylase 1 (brain, 67kDa) |
|
increases expression |
ISO |
2 |
171,673,200 |
171,717,661 |
RGD:6480464 |
CTD |
| G |
GAD1 |
glutamate decarboxylase 1 (brain, 67kDa) |
|
multiple interactions |
ISO |
2 |
171,673,200 |
171,717,661 |
RGD:6480464 |
CTD |
| G |
GADD45G |
growth arrest and DNA-damage-inducible, gamma |
|
increases expression |
ISO |
9 |
92,219,927 |
92,221,470 |
RGD:6480464 |
CTD |
| G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
|
increases expression |
EXP |
12 |
6,643,585 |
6,647,537 |
RGD:6480464 |
CTD |
| G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
|
multiple interactions |
ISO |
12 |
6,643,585 |
6,647,537 |
RGD:6480464 |
CTD |
| G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
|
multiple interactions |
EXP |
12 |
6,643,585 |
6,647,537 |
RGD:6480464 |
CTD |
| G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
|
multiple interactions |
ISO |
12 |
6,643,585 |
6,647,537 |
RGD:6480464 |
CTD |
| G |
GAST |
gastrin |
|
increases secretion |
ISO |
17 |
39,868,578 |
39,872,221 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
increases secretion |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
multiple interactions |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
multiple interactions |
EXP |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
multiple interactions |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
multiple interactions |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
increases abundance |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
multiple interactions |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
decreases secretion |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCG |
glucagon |
|
multiple interactions |
ISO |
2 |
162,999,379 |
163,008,914 |
RGD:6480464 |
CTD |
| G |
GCK |
glucokinase (hexokinase 4) |
|
multiple interactions |
ISO |
7 |
44,183,870 |
44,229,022 |
RGD:6480464 |
CTD |
| G |
GEM |
GTP binding protein overexpressed in skeletal muscle |
|
increases expression |
ISO |
8 |
95,261,481 |
95,274,547 |
RGD:6480464 |
CTD |
| G |
GH1 |
growth hormone 1 |
|
multiple interactions |
EXP |
17 |
61,994,563 |
61,996,198 |
RGD:6480464 |
CTD |
| G |
GJA1 |
gap junction protein, alpha 1, 43kDa |
|
increases expression |
ISO |
6 |
121,756,745 |
121,770,873 |
RGD:6480464 |
CTD |
| G |
GLA |
galactosidase, alpha |
|
increases expression |
ISO |
X |
100,652,779 |
100,663,001 |
RGD:6480464 |
CTD |
| G |
GLB1 |
galactosidase, beta 1 |
|
increases expression |
EXP |
3 |
33,038,100 |
33,138,694 |
RGD:6480464 |
CTD |
| G |
GLP1R |
glucagon-like peptide 1 receptor |
|
multiple interactions |
ISO |
6 |
39,016,557 |
39,055,520 |
RGD:6480464 |
CTD |
| G |
GLP1R |
glucagon-like peptide 1 receptor |
|
multiple interactions |
ISO |
6 |
39,016,557 |
39,055,520 |
RGD:6480464 |
CTD |
| G |
GNAI1 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 |
|
decreases expression |
ISO |
7 |
79,764,140 |
79,848,725 |
RGD:6480464 |
CTD |
| G |
GPD2 |
glycerol-3-phosphate dehydrogenase 2 (mitochondrial) |
|
multiple interactions |
ISO |
2 |
157,291,965 |
157,442,915 |
RGD:6480464 |
CTD |
| G |
GPD2 |
glycerol-3-phosphate dehydrogenase 2 (mitochondrial) |
|
multiple interactions |
ISO |
2 |
157,291,965 |
157,442,915 |
RGD:6480464 |
CTD |
| G |
GPD2 |
glycerol-3-phosphate dehydrogenase 2 (mitochondrial) |
|
multiple interactions |
ISO |
2 |
157,291,965 |
157,442,915 |
RGD:6480464 |
CTD |
| G |
GPX1 |
glutathione peroxidase 1 |
|
decreases expression |
ISO |
3 |
49,394,609 |
49,395,791 |
RGD:6480464 |
CTD |
| G |
GREM1 |
gremlin 1, DAN family BMP antagonist |
|
increases expression |
EXP |
15 |
33,010,205 |
33,026,870 |
RGD:6480464 |
CTD |
| G |
GREM1 |
gremlin 1, DAN family BMP antagonist |
|
increases expression |
EXP |
15 |
33,010,205 |
33,026,870 |
RGD:6480464 |
CTD |
| G |
GSK3B |
glycogen synthase kinase 3 beta |
|
multiple interactions |
ISO |
3 |
119,540,800 |
119,813,264 |
RGD:6480464 |
CTD |
| G |
GSR |
glutathione reductase |
|
multiple interactions |
EXP |
8 |
30,535,578 |
30,585,486 |
RGD:6480464 |
CTD |
| G |
HBEGF |
heparin-binding EGF-like growth factor |
|
increases expression |
ISO |
5 |
139,712,428 |
139,726,188 |
RGD:6480464 |
CTD |
| G |
HERPUD1 |
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 |
|
decreases expression |
ISO |
16 |
56,965,748 |
56,977,793 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
multiple interactions |
ISO |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
multiple interactions |
ISO |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
multiple interactions |
ISO |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
multiple interactions |
ISO |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HIST1H1C |
histone cluster 1, H1c |
|
increases expression |
ISO |
6 |
26,055,968 |
26,056,699 |
RGD:6480464 |
CTD |
| G |
HIST1H2BC |
histone cluster 1, H2bc |
|
increases expression |
ISO |
6 |
26,123,695 |
26,124,132 |
RGD:6480464 |
CTD |
| G |
HIST3H3 |
histone cluster 3, H3 |
|
multiple interactions |
ISO |
1 |
228,612,546 |
228,613,026 |
RGD:6480464 |
CTD |
| G |
HIST3H3 |
histone cluster 3, H3 |
|
multiple interactions |
ISO |
1 |
228,612,546 |
228,613,026 |
RGD:6480464 |
CTD |
| G |
HIST4H4 |
histone cluster 4, H4 |
|
multiple interactions |
ISO |
12 |
14,923,654 |
14,924,065 |
RGD:6480464 |
CTD |
| G |
HK1 |
hexokinase 1 |
|
increases expression |
ISO |
10 |
71,029,756 |
71,161,638 |
RGD:6480464 |
CTD |
| G |
HMGA2 |
high mobility group AT-hook 2 |
|
increases expression |
ISO |
12 |
66,218,240 |
66,360,071 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
decreases activity |
EXP |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HNF1A |
HNF1 homeobox A |
|
affects response to substance |
EXP |
12 |
121,416,549 |
121,440,315 |
RGD:6480464 |
CTD |
| G |
HNF4A |
hepatocyte nuclear factor 4, alpha |
|
multiple interactions |
EXP |
20 |
42,984,441 |
43,061,485 |
RGD:6480464 |
CTD |
| G |
HNF4A |
hepatocyte nuclear factor 4, alpha |
|
decreases expression |
EXP |
20 |
42,984,441 |
43,061,485 |
RGD:6480464 |
CTD |
| G |
HOXA2 |
homeobox A2 |
|
increases expression |
ISO |
7 |
27,139,973 |
27,142,394 |
RGD:6480464 |
CTD |
| G |
HRAS |
v-Ha-ras Harvey rat sarcoma viral oncogene homolog |
|
increases activity |
ISO |
11 |
532,242 |
535,550 |
RGD:6480464 |
CTD |
| G |
HRAS |
v-Ha-ras Harvey rat sarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
11 |
532,242 |
535,550 |
RGD:6480464 |
CTD |
| G |
HSD11B2 |
hydroxysteroid (11-beta) dehydrogenase 2 |
|
decreases expression |
ISO |
16 |
67,465,036 |
67,471,456 |
RGD:6480464 |
CTD |
| G |
HSP90B1 |
heat shock protein 90kDa beta (Grp94), member 1 |
|
decreases expression |
ISO |
12 |
104,324,112 |
104,341,708 |
RGD:6480464 |
CTD |
| G |
HSPA13 |
heat shock protein 70kDa family, member 13 |
|
decreases expression |
ISO |
21 |
15,743,436 |
15,755,509 |
RGD:6480464 |
CTD |
| G |
HSPA5 |
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) |
|
increases expression |
EXP |
9 |
127,997,127 |
128,003,666 |
RGD:6480464 |
CTD |
| G |
HSPA5 |
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) |
|
decreases expression |
ISO |
9 |
127,997,127 |
128,003,666 |
RGD:6480464 |
CTD |
| G |
HSPA5 |
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) |
|
increases expression |
ISO |
9 |
127,997,127 |
128,003,666 |
RGD:6480464 |
CTD |
| G |
HSPA5 |
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) |
|
increases expression |
EXP |
9 |
127,997,127 |
128,003,666 |
RGD:6480464 |
CTD |
| G |
HSPD1 |
heat shock 60kDa protein 1 (chaperonin) |
|
decreases expression |
EXP |
2 |
198,351,308 |
198,364,998 |
RGD:6480464 |
CTD |
| G |
HSPD1 |
heat shock 60kDa protein 1 (chaperonin) |
|
multiple interactions |
EXP |
2 |
198,351,308 |
198,364,998 |
RGD:6480464 |
CTD |
| G |
HYOU1 |
hypoxia up-regulated 1 |
|
decreases expression |
ISO |
11 |
118,914,896 |
118,927,925 |
RGD:6480464 |
CTD |
| G |
IAPP |
islet amyloid polypeptide |
|
multiple interactions |
ISO |
12 |
21,525,802 |
21,532,914 |
RGD:6480464 |
CTD |
| G |
IAPP |
islet amyloid polypeptide |
|
increases expression |
ISO |
12 |
21,525,802 |
21,532,914 |
RGD:6480464 |
CTD |
| G |
IAPP |
islet amyloid polypeptide |
|
multiple interactions |
EXP |
12 |
21,525,802 |
21,532,914 |
RGD:6480464 |
CTD |
| G |
ICAM1 |
intercellular adhesion molecule 1 |
|
increases expression |
EXP |
19 |
10,381,517 |
10,397,291 |
RGD:6480464 |
CTD |
| G |
ICAM1 |
intercellular adhesion molecule 1 |
|
increases expression |
EXP |
19 |
10,381,517 |
10,397,291 |
RGD:6480464 |
CTD |
| G |
ICAM1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
EXP |
19 |
10,381,517 |
10,397,291 |
RGD:6480464 |
CTD |
| G |
ICAM1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
EXP |
19 |
10,381,517 |
10,397,291 |
RGD:6480464 |
CTD |
| G |
ID1 |
inhibitor of DNA binding 1, dominant negative helix-loop-helix protein |
|
increases expression |
ISO |
20 |
30,193,086 |
30,194,318 |
RGD:6480464 |
CTD |
| G |
ID3 |
inhibitor of DNA binding 3, dominant negative helix-loop-helix protein |
|
increases expression |
ISO |
1 |
23,884,421 |
23,886,285 |
RGD:6480464 |
CTD |
| G |
IDE |
insulin-degrading enzyme |
|
decreases expression |
ISO |
10 |
94,211,441 |
94,333,852 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
multiple interactions |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
multiple interactions |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IGF1R |
insulin-like growth factor 1 receptor |
|
increases expression |
EXP |
15 |
99,192,761 |
99,507,759 |
RGD:6480464 |
CTD |
| G |
IGFBP4 |
insulin-like growth factor binding protein 4 |
|
decreases expression |
ISO |
17 |
38,599,676 |
38,613,982 |
RGD:6480464 |
CTD |
| G |
IL17A |
interleukin 17A |
|
increases expression |
ISO |
6 |
52,051,185 |
52,055,436 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases expression |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
increases secretion |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
ISO |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL1RN |
interleukin 1 receptor antagonist |
|
multiple interactions |
ISO |
2 |
113,875,470 |
113,891,593 |
RGD:6480464 |
CTD |
| G |
IL24 |
interleukin 24 |
|
increases expression |
ISO |
1 |
207,070,788 |
207,077,484 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
multiple interactions |
EXP |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL6 |
interleukin 6 (interferon, beta 2) |
|
increases expression |
EXP |
7 |
22,766,766 |
22,771,621 |
RGD:6480464 |
CTD |
| G |
IL8 |
interleukin 8 |
|
increases expression |
EXP |
4 |
74,606,223 |
74,609,433 |
RGD:6480464 |
CTD |
| G |
IL8 |
interleukin 8 |
|
multiple interactions |
EXP |
4 |
74,606,223 |
74,609,433 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
decreases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases uptake |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases expression |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases uptake |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
decreases expression |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
decreases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases activity |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases uptake |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases uptake |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
decreases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
ISO |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases uptake |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases uptake |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
multiple interactions |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INS |
insulin |
|
increases secretion |
EXP |
11 |
2,181,009 |
2,182,439 |
RGD:6480464 |
CTD |
| G |
INSR |
insulin receptor |
|
decreases degradation |
EXP |
19 |
7,112,266 |
7,294,011 |
RGD:6480464 |
CTD |
| G |
INSR |
insulin receptor |
|
increases expression |
EXP |
19 |
7,112,266 |
7,294,011 |
RGD:6480464 |
CTD |
| G |
INSR |
insulin receptor |
|
increases phosphorylation |
EXP |
19 |
7,112,266 |
7,294,011 |
RGD:6480464 |
CTD |
| G |
IRS1 |
insulin receptor substrate 1 |
|
multiple interactions |
EXP |
2 |
227,596,033 |
227,663,506 |
RGD:6480464 |
CTD |
| G |
IRS1 |
insulin receptor substrate 1 |
|
increases phosphorylation |
EXP |
2 |
227,596,033 |
227,663,506 |
RGD:6480464 |
CTD |
| G |
IRS2 |
insulin receptor substrate 2 |
|
increases phosphorylation |
EXP |
13 |
110,406,184 |
110,438,914 |
RGD:6480464 |
CTD |
| G |
ITGA2B |
integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) |
|
multiple interactions |
EXP |
17 |
42,449,550 |
42,466,873 |
RGD:6480464 |
CTD |
| G |
ITGB1 |
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) |
|
increases expression |
ISO |
10 |
33,189,246 |
33,247,293 |
RGD:6480464 |
CTD |
| G |
ITGB1 |
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) |
|
multiple interactions |
ISO |
10 |
33,189,246 |
33,247,293 |
RGD:6480464 |
CTD |
| G |
ITGB3 |
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) |
|
multiple interactions |
EXP |
17 |
45,331,208 |
45,390,077 |
RGD:6480464 |
CTD |
| G |
JAK2 |
Janus kinase 2 |
|
multiple interactions |
EXP |
9 |
4,985,245 |
5,128,183 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
multiple interactions |
EXP |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
multiple interactions |
EXP |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
multiple interactions |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
multiple interactions |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
increases expression |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
increases phosphorylation |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
increases expression |
EXP |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
increases expression |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
increases expression |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
increases phosphorylation |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
increases phosphorylation |
EXP |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
multiple interactions |
EXP |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUNB |
jun B proto-oncogene |
|
increases expression |
ISO |
19 |
12,902,310 |
12,904,125 |
RGD:6480464 |
CTD |
| G |
KCNMA1 |
potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
|
multiple interactions |
EXP |
10 |
78,629,359 |
79,397,577 |
RGD:6480464 |
CTD |
| G |
KCNMB1 |
potassium large conductance calcium-activated channel, subfamily M, beta member 1 |
|
multiple interactions |
EXP |
5 |
169,805,167 |
169,816,638 |
RGD:6480464 |
CTD |
| G |
KDR |
kinase insert domain receptor (a type III receptor tyrosine kinase) |
|
multiple interactions |
ISO |
4 |
55,944,426 |
55,991,762 |
RGD:6480464 |
CTD |
| G |
KLF10 |
Kruppel-like factor 10 |
|
multiple interactions |
EXP |
8 |
103,661,005 |
103,667,983 |
RGD:6480464 |
CTD |
| G |
KLF10 |
Kruppel-like factor 10 |
|
increases expression |
ISO |
8 |
103,661,005 |
103,667,983 |
RGD:6480464 |
CTD |
| G |
KLF6 |
Kruppel-like factor 6 |
|
increases expression |
ISO |
10 |
3,818,188 |
3,827,473 |
RGD:6480464 |
CTD |
| G |
KLF9 |
Kruppel-like factor 9 |
|
increases expression |
ISO |
9 |
72,999,513 |
73,029,573 |
RGD:6480464 |
CTD |
| G |
LAMB1 |
laminin, beta 1 |
|
multiple interactions |
ISO |
7 |
107,564,246 |
107,643,804 |
RGD:6480464 |
CTD |
| G |
LAMB2 |
laminin, beta 2 (laminin S) |
|
multiple interactions |
ISO |
3 |
49,158,547 |
49,170,599 |
RGD:6480464 |
CTD |
| G |
LAMB3 |
laminin, beta 3 |
|
multiple interactions |
ISO |
1 |
209,788,215 |
209,825,820 |
RGD:6480464 |
CTD |
| G |
LAMC1 |
laminin, gamma 1 (formerly LAMB2) |
|
multiple interactions |
ISO |
1 |
182,992,595 |
183,114,727 |
RGD:6480464 |
CTD |
| G |
LAMP2 |
lysosomal-associated membrane protein 2 |
|
multiple interactions |
EXP |
X |
119,560,003 |
119,603,204 |
RGD:6480464 |
CTD |
| G |
LCT |
lactase |
|
multiple interactions |
ISO |
2 |
136,545,415 |
136,594,750 |
RGD:6480464 |
CTD |
| G |
LCT |
lactase |
|
increases hydrolysis |
ISO |
2 |
136,545,415 |
136,594,750 |
RGD:6480464 |
CTD |
| G |
LEP |
leptin |
|
increases expression |
ISO |
7 |
127,881,331 |
127,897,682 |
RGD:6480464 |
CTD |
| G |
LEP |
leptin |
|
multiple interactions |
ISO |
7 |
127,881,331 |
127,897,682 |
RGD:6480464 |
CTD |
| G |
LEP |
leptin |
|
multiple interactions |
EXP |
7 |
127,881,331 |
127,897,682 |
RGD:6480464 |
CTD |
| G |
LEP |
leptin |
|
increases response to substance |
EXP |
7 |
127,881,331 |
127,897,682 |
RGD:6480464 |
CTD |
| G |
LEP |
leptin |
|
multiple interactions |
ISO |
7 |
127,881,331 |
127,897,682 |
RGD:6480464 |
CTD |
| G |
LEP |
leptin |
|
increases secretion |
ISO |
7 |
127,881,331 |
127,897,682 |
RGD:6480464 |
CTD |
| G |
LEP |
leptin |
|
increases expression |
ISO |
7 |
127,881,331 |
127,897,682 |
RGD:6480464 |
CTD |
| G |
LEPR |
leptin receptor |
|
decreases response to substance |
ISO |
1 |
65,886,335 |
66,103,176 |
RGD:6480464 |
CTD |
| G |
LEPR |
leptin receptor |
|
affects abundance |
ISO |
1 |
65,886,335 |
66,103,176 |
RGD:6480464 |
CTD |
| G |
LIF |
leukemia inhibitory factor |
|
multiple interactions |
EXP |
22 |
30,636,436 |
30,642,840 |
RGD:6480464 |
CTD |
| G |
LIF |
leukemia inhibitory factor |
|
increases expression |
EXP |
22 |
30,636,436 |
30,642,840 |
RGD:6480464 |
CTD |
| G |
LIF |
leukemia inhibitory factor |
|
increases expression |
ISO |
22 |
30,636,436 |
30,642,840 |
RGD:6480464 |
CTD |
| G |
LIPG |
lipase, endothelial |
|
decreases expression |
ISO |
18 |
47,088,427 |
47,119,278 |
RGD:6480464 |
CTD |
| G |
LPL |
lipoprotein lipase |
|
multiple interactions |
EXP |
8 |
19,796,582 |
19,824,770 |
RGD:6480464 |
CTD |
| G |
MAFA |
v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) |
|
multiple interactions |
EXP |
8 |
144,510,230 |
144,512,602 |
RGD:6480464 |
CTD |
| G |
MAFA |
v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) |
|
multiple interactions |
ISO |
8 |
144,510,230 |
144,512,602 |
RGD:6480464 |
CTD |
| G |
MAFF |
v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) |
|
increases expression |
ISO |
22 |
38,597,939 |
38,612,518 |
RGD:6480464 |
CTD |
| G |
MAGT1 |
magnesium transporter 1 |
|
decreases expression |
ISO |
X |
77,081,861 |
77,151,065 |
RGD:6480464 |
CTD |
| G |
MAP3K5 |
mitogen-activated protein kinase kinase kinase 5 |
|
increases expression |
EXP |
6 |
136,878,187 |
137,113,656 |
RGD:6480464 |
CTD |
| G |
MAP3K5 |
mitogen-activated protein kinase kinase kinase 5 |
|
multiple interactions |
EXP |
6 |
136,878,187 |
137,113,656 |
RGD:6480464 |
CTD |
| G |
MAP3K5 |
mitogen-activated protein kinase kinase kinase 5 |
|
multiple interactions |
EXP |
6 |
136,878,187 |
137,113,656 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases expression |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
decreases phosphorylation |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases activity |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases phosphorylation |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
affects phosphorylation |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases phosphorylation |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases phosphorylation |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases phosphorylation |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases phosphorylation |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK14 |
mitogen-activated protein kinase 14 |
|
multiple interactions |
EXP |
6 |
35,995,454 |
36,079,013 |
RGD:6480464 |
CTD |
| G |
MAPK14 |
mitogen-activated protein kinase 14 |
|
increases activity |
EXP |
6 |
35,995,454 |
36,079,013 |
RGD:6480464 |
CTD |
| G |
MAPK14 |
mitogen-activated protein kinase 14 |
|
decreases phosphorylation |
EXP |
6 |
35,995,454 |
36,079,013 |
RGD:6480464 |
CTD |
| G |
MAPK14 |
mitogen-activated protein kinase 14 |
|
multiple interactions |
ISO |
6 |
35,995,454 |
36,079,013 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases expression |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
affects phosphorylation |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases phosphorylation |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases activity |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
decreases phosphorylation |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases phosphorylation |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases phosphorylation |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases phosphorylation |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases phosphorylation |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
increases phosphorylation |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK9 |
mitogen-activated protein kinase 9 |
|
increases phosphorylation |
ISO |
5 |
179,660,594 |
179,719,071 |
RGD:6480464 |
CTD |
| G |
MDK |
midkine (neurite growth-promoting factor 2) |
|
increases expression |
ISO |
11 |
46,402,334 |
46,405,387 |
RGD:6480464 |
CTD |
| G |
MGAM |
maltase-glucoamylase (alpha-glucosidase) |
|
multiple interactions |
ISO |
7 |
141,695,679 |
141,806,547 |
RGD:6480464 |
CTD |
| G |
MIR146A |
microRNA 146a |
|
increases expression |
EXP |
5 |
159,912,359 |
159,912,457 |
RGD:6480464 |
CTD |
| G |
MIR146A |
microRNA 146a |
|
multiple interactions |
EXP |
5 |
159,912,359 |
159,912,457 |
RGD:6480464 |
CTD |
| G |
MIR148A |
microRNA 148a |
|
decreases expression |
EXP |
7 |
25,989,539 |
25,989,606 |
RGD:6480464 |
CTD |
| G |
MLXIPL |
MLX interacting protein-like |
|
increases expression |
ISO |
7 |
73,007,524 |
73,038,870 |
RGD:6480464 |
CTD |
| G |
MLXIPL |
MLX interacting protein-like |
|
increases expression |
ISO |
7 |
73,007,524 |
73,038,870 |
RGD:6480464 |
CTD |
| G |
MLXIPL |
MLX interacting protein-like |
|
increases expression |
ISO |
7 |
73,007,524 |
73,038,870 |
RGD:6480464 |
CTD |
| G |
MME |
membrane metallo-endopeptidase |
|
decreases expression |
ISO |
3 |
154,797,436 |
154,901,518 |
RGD:6480464 |
CTD |
| G |
MMP1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
multiple interactions |
EXP |
11 |
102,660,641 |
102,668,966 |
RGD:6480464 |
CTD |
| G |
MMP2 |
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) |
|
increases expression |
ISO |
16 |
55,513,081 |
55,540,586 |
RGD:6480464 |
CTD |
| G |
MMP2 |
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) |
|
multiple interactions |
ISO |
16 |
55,513,081 |
55,540,586 |
RGD:6480464 |
CTD |
| G |
MMP2 |
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) |
|
multiple interactions |
ISO |
16 |
55,513,081 |
55,540,586 |
RGD:6480464 |
CTD |
| G |
MMP9 |
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
|
increases activity |
ISO |
20 |
44,637,547 |
44,645,200 |
RGD:6480464 |
CTD |
| G |
MMP9 |
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
|
multiple interactions |
ISO |
20 |
44,637,547 |
44,645,200 |
RGD:6480464 |
CTD |
| G |
MRAS |
muscle RAS oncogene homolog |
|
increases activity |
ISO |
3 |
138,066,490 |
138,124,377 |
RGD:6480464 |
CTD |
| G |
MRAS |
muscle RAS oncogene homolog |
|
multiple interactions |
ISO |
3 |
138,066,490 |
138,124,377 |
RGD:6480464 |
CTD |
| G |
MT-ATP6 |
mitochondrially encoded ATP synthase 6 |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
MTM1 |
myotubularin 1 |
|
decreases expression |
ISO |
X |
149,737,047 |
149,841,616 |
RGD:6480464 |
CTD |
| G |
MTX1 |
metaxin 1 |
|
increases expression |
ISO |
1 |
155,178,490 |
155,183,625 |
RGD:6480464 |
CTD |
| G |
MYC |
v-myc myelocytomatosis viral oncogene homolog (avian) |
|
multiple interactions |
EXP |
8 |
128,748,315 |
128,753,680 |
RGD:6480464 |
CTD |
| G |
MYC |
v-myc myelocytomatosis viral oncogene homolog (avian) |
|
multiple interactions |
ISO |
8 |
128,748,315 |
128,753,680 |
RGD:6480464 |
CTD |
| G |
MYH2 |
myosin, heavy chain 2, skeletal muscle, adult |
|
multiple interactions |
ISO |
17 |
10,424,465 |
10,453,017 |
RGD:6480464 |
CTD |
| G |
MYLK |
myosin light chain kinase |
|
multiple interactions |
ISO |
3 |
123,331,143 |
123,603,149 |
RGD:6480464 |
CTD |
| G |
MYLK |
myosin light chain kinase |
|
increases uptake |
ISO |
3 |
123,331,143 |
123,603,149 |
RGD:6480464 |
CTD |
| G |
NAPA |
N-ethylmaleimide-sensitive factor attachment protein, alpha |
|
decreases expression |
EXP |
19 |
47,990,891 |
48,018,515 |
RGD:6480464 |
CTD |
| G |
NBEA |
neurobeachin |
|
decreases expression |
ISO |
13 |
35,516,424 |
36,246,874 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
increases expression |
ISO |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
increases expression |
ISO |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
multiple interactions |
ISO |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
multiple interactions |
EXP |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
affects localization |
EXP |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
increases expression |
EXP |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
multiple interactions |
EXP |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
multiple interactions |
ISO |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NCF1 |
neutrophil cytosolic factor 1 |
|
increases expression |
ISO |
7 |
74,188,309 |
74,203,659 |
RGD:6480464 |
CTD |
| G |
NDEL1 |
nudE nuclear distribution E homolog (A. nidulans)-like 1 |
|
increases expression |
ISO |
17 |
8,339,170 |
8,371,495 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
increases expression |
EXP |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
increases localization |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
multiple interactions |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFE2L2 |
nuclear factor (erythroid-derived 2)-like 2 |
|
decreases expression |
ISO |
2 |
178,095,031 |
178,129,859 |
RGD:6480464 |
CTD |
| G |
NFKB1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
increases expression |
EXP |
4 |
103,422,486 |
103,538,459 |
RGD:6480464 |
CTD |
| G |
NFKB1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
EXP |
4 |
103,422,486 |
103,538,459 |
RGD:6480464 |
CTD |
| G |
NFKB1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
increases expression |
EXP |
4 |
103,422,486 |
103,538,459 |
RGD:6480464 |
CTD |
| G |
NFKB1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
4 |
103,422,486 |
103,538,459 |
RGD:6480464 |
CTD |
| G |
NFKBIA |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
14 |
35,870,716 |
35,873,960 |
RGD:6480464 |
CTD |
| G |
NFKBIA |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
14 |
35,870,716 |
35,873,960 |
RGD:6480464 |
CTD |
| G |
NFKBIA |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
ISO |
14 |
35,870,716 |
35,873,960 |
RGD:6480464 |
CTD |
| G |
NFKBIA |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases phosphorylation |
EXP |
14 |
35,870,716 |
35,873,960 |
RGD:6480464 |
CTD |
| G |
NFKBIA |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
14 |
35,870,716 |
35,873,960 |
RGD:6480464 |
CTD |
| G |
NFKBIA |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
14 |
35,870,716 |
35,873,960 |
RGD:6480464 |
CTD |
| G |
NGF |
nerve growth factor (beta polypeptide) |
|
decreases activity |
ISO |
1 |
115,828,537 |
115,880,857 |
RGD:6480464 |
CTD |
| G |
NKX6-1 |
NK6 homeobox 1 |
|
multiple interactions |
EXP |
4 |
85,414,436 |
85,419,387 |
RGD:6480464 |
CTD |
| G |
NOS1 |
nitric oxide synthase 1 (neuronal) |
|
decreases expression |
EXP |
12 |
117,645,947 |
117,799,607 |
RGD:6480464 |
CTD |
| G |
NOS1 |
nitric oxide synthase 1 (neuronal) |
|
multiple interactions |
EXP |
12 |
117,645,947 |
117,799,607 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
multiple interactions |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases phosphorylation |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
increases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
multiple interactions |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
multiple interactions |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
multiple interactions |
ISO |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
increases expression |
ISO |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
multiple interactions |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
increases O-linked glycosylation |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases phosphorylation |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
increases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
multiple interactions |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
decreases expression |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NPPA |
natriuretic peptide A |
|
multiple interactions |
ISO |
1 |
11,905,766 |
11,907,840 |
RGD:6480464 |
CTD |
| G |
NPY |
neuropeptide Y |
|
decreases expression |
ISO |
7 |
24,323,807 |
24,331,484 |
RGD:6480464 |
CTD |
| G |
NPY |
neuropeptide Y |
|
decreases expression |
ISO |
7 |
24,323,807 |
24,331,484 |
RGD:6480464 |
CTD |
| G |
NPY |
neuropeptide Y |
|
increases expression |
ISO |
7 |
24,323,807 |
24,331,484 |
RGD:6480464 |
CTD |
| G |
NQO1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases expression |
ISO |
16 |
69,743,304 |
69,760,533 |
RGD:6480464 |
CTD |
| G |
NR0B2 |
nuclear receptor subfamily 0, group B, member 2 |
|
multiple interactions |
EXP |
1 |
27,237,975 |
27,240,567 |
RGD:6480464 |
CTD |
| G |
NR1D2 |
nuclear receptor subfamily 1, group D, member 2 |
|
decreases expression |
ISO |
3 |
23,986,751 |
24,022,109 |
RGD:6480464 |
CTD |
| G |
NR1I2 |
nuclear receptor subfamily 1, group I, member 2 |
|
decreases activity |
EXP |
3 |
119,499,331 |
119,537,332 |
RGD:6480464 |
CTD |
| G |
NR1I2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
EXP |
3 |
119,499,331 |
119,537,332 |
RGD:6480464 |
CTD |
| G |
NR2F1 |
nuclear receptor subfamily 2, group F, member 1 |
|
multiple interactions |
EXP |
5 |
92,919,043 |
92,929,788 |
RGD:6480464 |
CTD |
| G |
NR3C1 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions |
ISO |
5 |
142,657,496 |
142,815,077 |
RGD:6480464 |
CTD |
| G |
NRG1 |
neuregulin 1 |
|
multiple interactions |
ISO |
8 |
31,496,820 |
32,622,558 |
RGD:6480464 |
CTD |
| G |
NRG1 |
neuregulin 1 |
|
increases transport |
ISO |
8 |
31,496,820 |
32,622,558 |
RGD:6480464 |
CTD |
| G |
NRIP2 |
nuclear receptor interacting protein 2 |
|
decreases expression |
ISO |
12 |
2,934,514 |
2,944,221 |
RGD:6480464 |
CTD |
| G |
NUCB2 |
nucleobindin 2 |
|
decreases expression |
ISO |
11 |
17,298,286 |
17,353,070 |
RGD:6480464 |
CTD |
| G |
NUPR1 |
nuclear protein, transcriptional regulator, 1 |
|
decreases abundance |
EXP |
16 |
28,548,662 |
28,550,495 |
RGD:6480464 |
CTD |
| G |
OAT |
ornithine aminotransferase |
|
multiple interactions |
ISO |
10 |
126,085,872 |
126,107,545 |
RGD:6480464 |
CTD |
| G |
OGT |
O-linked N-acetylglucosamine (GlcNAc) transferase |
|
decreases expression |
ISO |
X |
70,752,912 |
70,795,747 |
RGD:6480464 |
CTD |
| G |
ORC4 |
origin recognition complex, subunit 4 |
|
decreases expression |
ISO |
2 |
148,687,966 |
148,779,173 |
RGD:6480464 |
CTD |
| G |
OXR1 |
oxidation resistance 1 |
|
decreases expression |
ISO |
8 |
107,282,406 |
107,764,922 |
RGD:6480464 |
CTD |
| G |
P2RX7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
|
increases expression |
ISO |
12 |
121,570,622 |
121,624,354 |
RGD:6480464 |
CTD |
| G |
P4HA1 |
prolyl 4-hydroxylase, alpha polypeptide I |
|
increases expression |
EXP |
10 |
74,766,975 |
74,856,732 |
RGD:6480464 |
CTD |
| G |
PAIP2 |
poly(A) binding protein interacting protein 2 |
|
multiple interactions |
EXP |
5 |
138,677,519 |
138,705,409 |
RGD:6480464 |
CTD |
| G |
PAK3 |
p21 protein (Cdc42/Rac)-activated kinase 3 |
|
decreases expression |
ISO |
X |
110,187,513 |
110,464,173 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
EXP |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
increases activity |
ISO |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PARP1 |
poly (ADP-ribose) polymerase 1 |
|
decreases expression |
ISO |
1 |
226,548,392 |
226,595,801 |
RGD:6480464 |
CTD |
| G |
PAX3 |
paired box 3 |
|
multiple interactions |
ISO |
2 |
223,064,606 |
223,163,715 |
RGD:6480464 |
CTD |
| G |
PAX3 |
paired box 3 |
|
decreases expression |
ISO |
2 |
223,064,606 |
223,163,715 |
RGD:6480464 |
CTD |
| G |
PAX3 |
paired box 3 |
|
decreases expression |
ISO |
2 |
223,064,606 |
223,163,715 |
RGD:6480464 |
CTD |
| G |
PAX6 |
paired box 6 |
|
decreases expression |
ISO |
11 |
31,806,340 |
31,839,509 |
RGD:6480464 |
CTD |
| G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 (soluble) |
|
multiple interactions |
ISO |
20 |
56,136,137 |
56,141,513 |
RGD:6480464 |
CTD |
| G |
PCMTD1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
|
decreases expression |
ISO |
8 |
52,730,140 |
52,811,735 |
RGD:6480464 |
CTD |
| G |
PCNA |
proliferating cell nuclear antigen |
|
increases expression |
ISO |
20 |
5,095,599 |
5,107,268 |
RGD:6480464 |
CTD |
| G |
PCNA |
proliferating cell nuclear antigen |
|
multiple interactions |
ISO |
20 |
5,095,599 |
5,107,268 |
RGD:6480464 |
CTD |
| G |
PDIA3 |
protein disulfide isomerase family A, member 3 |
|
decreases expression |
ISO |
15 |
44,038,590 |
44,064,804 |
RGD:6480464 |
CTD |
| G |
PDIA4 |
protein disulfide isomerase family A, member 4 |
|
decreases expression |
ISO |
7 |
148,700,154 |
148,725,782 |
RGD:6480464 |
CTD |
| G |
PDIA6 |
protein disulfide isomerase family A, member 6 |
|
decreases expression |
ISO |
2 |
10,923,517 |
10,952,960 |
RGD:6480464 |
CTD |
| G |
PDK1 |
pyruvate dehydrogenase kinase, isozyme 1 |
|
multiple interactions |
ISO |
2 |
173,420,779 |
173,463,862 |
RGD:6480464 |
CTD |
| G |
PDK4 |
pyruvate dehydrogenase kinase, isozyme 4 |
|
increases expression |
ISO |
7 |
95,212,809 |
95,225,925 |
RGD:6480464 |
CTD |
| G |
PDX1 |
pancreatic and duodenal homeobox 1 |
|
affects localization |
EXP |
13 |
28,494,168 |
28,500,451 |
RGD:6480464 |
CTD |
| G |
PDX1 |
pancreatic and duodenal homeobox 1 |
|
multiple interactions |
ISO |
13 |
28,494,168 |
28,500,451 |
RGD:6480464 |
CTD |
| G |
PDX1 |
pancreatic and duodenal homeobox 1 |
|
affects localization |
ISO |
13 |
28,494,168 |
28,500,451 |
RGD:6480464 |
CTD |
| G |
PDX1 |
pancreatic and duodenal homeobox 1 |
|
multiple interactions |
EXP |
13 |
28,494,168 |
28,500,451 |
RGD:6480464 |
CTD |
| G |
PDX1 |
pancreatic and duodenal homeobox 1 |
|
increases activity |
ISO |
13 |
28,494,168 |
28,500,451 |
RGD:6480464 |
CTD |
| G |
PDX1 |
pancreatic and duodenal homeobox 1 |
|
multiple interactions |
ISO |
13 |
28,494,168 |
28,500,451 |
RGD:6480464 |
CTD |
| G |
PEBP1 |
phosphatidylethanolamine binding protein 1 |
|
increases expression |
EXP |
12 |
118,573,870 |
118,583,390 |
RGD:6480464 |
CTD |
| G |
PHLDA1 |
pleckstrin homology-like domain, family A, member 1 |
|
increases expression |
ISO |
12 |
76,419,227 |
76,425,556 |
RGD:6480464 |
CTD |
| G |
PIGA |
phosphatidylinositol glycan anchor biosynthesis, class A |
|
decreases expression |
ISO |
X |
15,337,573 |
15,353,676 |
RGD:6480464 |
CTD |
| G |
PIK3R1 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
|
multiple interactions |
EXP |
5 |
67,511,584 |
67,597,649 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases expression |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
multiple interactions |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases activity |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases expression |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases expression |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases expression |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases expression |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases expression |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PKLR |
pyruvate kinase, liver and RBC |
|
increases expression |
ISO |
1 |
155,259,084 |
155,271,225 |
RGD:6480464 |
CTD |
| G |
PLAGL1 |
pleiomorphic adenoma gene-like 1 |
|
decreases expression |
ISO |
6 |
144,261,437 |
144,385,735 |
RGD:6480464 |
CTD |
| G |
PLAT |
plasminogen activator, tissue |
|
increases expression |
ISO |
8 |
42,032,236 |
42,065,194 |
RGD:6480464 |
CTD |
| G |
PLK1 |
polo-like kinase 1 |
|
increases expression |
ISO |
16 |
23,690,201 |
23,701,688 |
RGD:6480464 |
CTD |
| G |
PLOD2 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 |
|
increases expression |
ISO |
3 |
145,787,227 |
145,879,282 |
RGD:6480464 |
CTD |
| G |
PLS3 |
plastin 3 |
|
increases expression |
EXP |
X |
114,795,177 |
114,885,181 |
RGD:6480464 |
CTD |
| G |
POMC |
proopiomelanocortin |
|
decreases expression |
ISO |
2 |
25,383,722 |
25,391,559 |
RGD:6480464 |
CTD |
| G |
POMC |
proopiomelanocortin |
|
multiple interactions |
ISO |
2 |
25,383,722 |
25,391,559 |
RGD:6480464 |
CTD |
| G |
PON2 |
paraoxonase 2 |
|
affects abundance |
EXP |
7 |
95,034,174 |
95,064,384 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
decreases expression |
EXP |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
multiple interactions |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
affects abundance |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
affects metabolic processing |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
multiple interactions |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
multiple interactions |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
multiple interactions |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
multiple interactions |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
multiple interactions |
EXP |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARA |
peroxisome proliferator-activated receptor alpha |
|
multiple interactions |
ISO |
22 |
46,546,499 |
46,639,653 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
decreases expression |
ISO |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
EXP |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARG |
peroxisome proliferator-activated receptor gamma |
|
decreases expression |
EXP |
3 |
12,329,349 |
12,475,855 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
EXP |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
increases acetylation |
EXP |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
decreases expression |
EXP |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
EXP |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PRKAA1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
|
multiple interactions |
EXP |
5 |
40,759,481 |
40,798,297 |
RGD:6480464 |
CTD |
| G |
PRKAA1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
|
multiple interactions |
EXP |
5 |
40,759,481 |
40,798,297 |
RGD:6480464 |
CTD |
| G |
PRKAA1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
|
multiple interactions |
ISO |
5 |
40,759,481 |
40,798,297 |
RGD:6480464 |
CTD |
| G |
PRKAA1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
|
multiple interactions |
EXP |
5 |
40,759,481 |
40,798,297 |
RGD:6480464 |
CTD |
| G |
PRKAA2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
|
multiple interactions |
ISO |
1 |
57,110,990 |
57,181,008 |
RGD:6480464 |
CTD |
| G |
PRKAA2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
|
multiple interactions |
ISO |
1 |
57,110,990 |
57,181,008 |
RGD:6480464 |
CTD |
| G |
PRKAA2 |
protein kinase, AMP-activated, alpha 2 catalytic subunit |
|
affects response to substance |
ISO |
1 |
57,110,990 |
57,181,008 |
RGD:6480464 |
CTD |
| G |
PRKAR2B |
protein kinase, cAMP-dependent, regulatory, type II, beta |
|
increases expression |
ISO |
7 |
106,685,178 |
106,802,256 |
RGD:6480464 |
CTD |
| G |
PRKCA |
protein kinase C, alpha |
|
multiple interactions |
ISO |
17 |
64,298,926 |
64,806,862 |
RGD:6480464 |
CTD |
| G |
PRKCB |
protein kinase C, beta |
|
multiple interactions |
ISO |
16 |
23,847,300 |
24,231,932 |
RGD:6480464 |
CTD |
| G |
PRKCD |
protein kinase C, delta |
|
multiple interactions |
ISO |
3 |
53,195,223 |
53,226,733 |
RGD:6480464 |
CTD |
| G |
PRKCD |
protein kinase C, delta |
|
increases expression |
ISO |
3 |
53,195,223 |
53,226,733 |
RGD:6480464 |
CTD |
| G |
PRKCH |
protein kinase C, eta |
|
decreases expression |
ISO |
14 |
61,788,515 |
62,017,698 |
RGD:6480464 |
CTD |
| G |
PRKCZ |
protein kinase C, zeta |
|
multiple interactions |
ISO |
1 |
1,981,909 |
2,116,834 |
RGD:6480464 |
CTD |
| G |
PRKG1 |
protein kinase, cGMP-dependent, type I |
|
multiple interactions |
ISO |
10 |
52,750,911 |
54,058,110 |
RGD:6480464 |
CTD |
| G |
PRKG1 |
protein kinase, cGMP-dependent, type I |
|
decreases expression |
ISO |
10 |
52,750,911 |
54,058,110 |
RGD:6480464 |
CTD |
| G |
PRKG1 |
protein kinase, cGMP-dependent, type I |
|
multiple interactions |
ISO |
10 |
52,750,911 |
54,058,110 |
RGD:6480464 |
CTD |
| G |
PRKG1 |
protein kinase, cGMP-dependent, type I |
|
decreases expression |
ISO |
10 |
52,750,911 |
54,058,110 |
RGD:6480464 |
CTD |
| G |
PRKG2 |
protein kinase, cGMP-dependent, type II |
|
increases expression |
ISO |
4 |
82,009,837 |
82,126,215 |
RGD:6480464 |
CTD |
| G |
PRNP |
prion protein |
|
multiple interactions |
EXP |
20 |
4,666,797 |
4,682,234 |
RGD:6480464 |
CTD |
| G |
PRPF40A |
PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) |
|
decreases expression |
ISO |
2 |
153,508,107 |
153,573,975 |
RGD:6480464 |
CTD |
| G |
PSMA1 |
proteasome (prosome, macropain) subunit, alpha type, 1 |
|
decreases expression |
EXP |
11 |
14,526,422 |
14,665,180 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
increases expression |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
EXP |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
PVR |
poliovirus receptor |
|
increases expression |
ISO |
19 |
45,147,098 |
45,169,429 |
RGD:6480464 |
CTD |
| G |
PYGL |
phosphorylase, glycogen, liver |
|
multiple interactions |
ISO |
14 |
51,371,935 |
51,411,248 |
RGD:6480464 |
CTD |
| G |
PYY |
peptide YY |
|
affects expression |
ISO |
17 |
42,030,106 |
42,081,837 |
RGD:6480464 |
CTD |
| G |
RAC1 |
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) |
|
multiple interactions |
EXP |
7 |
6,414,126 |
6,443,598 |
RGD:6480464 |
CTD |
| G |
RAC1 |
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) |
|
multiple interactions |
EXP |
7 |
6,414,126 |
6,443,598 |
RGD:6480464 |
CTD |
| G |
RAC1 |
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) |
|
affects localization |
EXP |
7 |
6,414,126 |
6,443,598 |
RGD:6480464 |
CTD |
| G |
RAC1 |
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) |
|
increases localization |
EXP |
7 |
6,414,126 |
6,443,598 |
RGD:6480464 |
CTD |
| G |
RAMP2 |
receptor (G protein-coupled) activity modifying protein 2 |
|
increases expression |
ISO |
17 |
40,913,212 |
40,915,059 |
RGD:6480464 |
CTD |
| G |
RAMP3 |
receptor (G protein-coupled) activity modifying protein 3 |
|
increases expression |
ISO |
7 |
45,197,367 |
45,223,849 |
RGD:6480464 |
CTD |
| G |
RBM3 |
RNA binding motif (RNP1, RRM) protein 3 |
|
increases expression |
EXP |
X |
48,432,741 |
48,439,553 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
affects localization |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases expression |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases activity |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
decreases phosphorylation |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases phosphorylation |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases activity |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases phosphorylation |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
RELA |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
11 |
65,421,067 |
65,430,443 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases expression |
ISO |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
RET |
ret proto-oncogene |
|
increases expression |
ISO |
10 |
43,572,517 |
43,625,799 |
RGD:6480464 |
CTD |
| G |
RETN |
resistin |
|
decreases uptake |
EXP |
19 |
7,733,972 |
7,735,340 |
RGD:6480464 |
CTD |
| G |
RHOB |
ras homolog family member B |
|
increases expression |
ISO |
2 |
20,646,835 |
20,649,201 |
RGD:6480464 |
CTD |
| G |
RPS12 |
ribosomal protein S12 |
|
decreases expression |
EXP |
6 |
133,135,708 |
133,138,703 |
RGD:6480464 |
CTD |
| G |
RPS6 |
ribosomal protein S6 |
|
multiple interactions |
ISO |
9 |
19,376,254 |
19,380,235 |
RGD:6480464 |
CTD |
| G |
RPSA |
ribosomal protein SA |
|
decreases expression |
EXP |
3 |
39,448,204 |
39,454,033 |
RGD:6480464 |
CTD |
| G |
RUNX2 |
runt-related transcription factor 2 |
|
increases expression |
ISO |
6 |
45,296,054 |
45,518,819 |
RGD:6480464 |
CTD |
| G |
SAA2 |
serum amyloid A2 |
|
increases expression |
ISO |
11 |
18,259,780 |
18,270,221 |
RGD:6480464 |
CTD |
| G |
SCD |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
increases expression |
ISO |
10 |
102,106,772 |
102,124,588 |
RGD:6480464 |
CTD |
| G |
SEC11C |
SEC11 homolog C (S. cerevisiae) |
|
decreases expression |
ISO |
18 |
56,807,125 |
56,826,064 |
RGD:6480464 |
CTD |
| G |
SEC13 |
SEC13 homolog (S. cerevisiae) |
|
decreases expression |
EXP |
3 |
10,342,615 |
10,362,858 |
RGD:6480464 |
CTD |
| G |
SELE |
selectin E |
|
increases expression |
EXP |
1 |
169,691,781 |
169,703,220 |
RGD:6480464 |
CTD |
| G |
SELE |
selectin E |
|
multiple interactions |
EXP |
1 |
169,691,781 |
169,703,220 |
RGD:6480464 |
CTD |
| G |
SELE |
selectin E |
|
multiple interactions |
EXP |
1 |
169,691,781 |
169,703,220 |
RGD:6480464 |
CTD |
| G |
SELE |
selectin E |
|
increases expression |
EXP |
1 |
169,691,781 |
169,703,220 |
RGD:6480464 |
CTD |
| G |
SELP |
selectin P (granule membrane protein 140kDa, antigen CD62) |
|
multiple interactions |
EXP |
1 |
169,558,087 |
169,599,377 |
RGD:6480464 |
CTD |
| G |
SEMA3A |
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A |
|
decreases expression |
ISO |
7 |
83,587,659 |
83,824,217 |
RGD:6480464 |
CTD |
| G |
SEPP1 |
selenoprotein P, plasma, 1 |
|
increases expression |
ISO |
5 |
42,799,982 |
42,812,024 |
RGD:6480464 |
CTD |
| G |
SEPP1 |
selenoprotein P, plasma, 1 |
|
increases secretion |
ISO |
5 |
42,799,982 |
42,812,024 |
RGD:6480464 |
CTD |
| G |
SEPP1 |
selenoprotein P, plasma, 1 |
|
multiple interactions |
ISO |
5 |
42,799,982 |
42,812,024 |
RGD:6480464 |
CTD |
| G |
SERPINE1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
increases secretion |
EXP |
7 |
100,770,370 |
100,782,547 |
RGD:6480464 |
CTD |
| G |
SERPINE1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
EXP |
7 |
100,770,370 |
100,782,547 |
RGD:6480464 |
CTD |
| G |
SERPINE1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
ISO |
7 |
100,770,370 |
100,782,547 |
RGD:6480464 |
CTD |
| G |
SERPINE1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
EXP |
7 |
100,770,370 |
100,782,547 |
RGD:6480464 |
CTD |
| G |
SERPINE1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
ISO |
7 |
100,770,370 |
100,782,547 |
RGD:6480464 |
CTD |
| G |
SGK1 |
serum/glucocorticoid regulated kinase 1 |
|
increases expression |
ISO |
6 |
134,490,384 |
134,639,196 |
RGD:6480464 |
CTD |
| G |
SH3BP2 |
SH3-domain binding protein 2 |
|
increases expression |
ISO |
4 |
2,794,750 |
2,842,823 |
RGD:6480464 |
CTD |
| G |
SHBG |
sex hormone-binding globulin |
|
multiple interactions |
EXP |
17 |
7,517,382 |
7,536,700 |
RGD:6480464 |
CTD |
| G |
SHBG |
sex hormone-binding globulin |
|
decreases expression |
EXP |
17 |
7,517,382 |
7,536,700 |
RGD:6480464 |
CTD |
| G |
SI |
sucrase-isomaltase (alpha-glucosidase) |
|
increases expression |
ISO |
3 |
164,696,686 |
164,796,283 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
multiple interactions |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
increases response to substance |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
decreases expression |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
multiple interactions |
EXP |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
multiple interactions |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
decreases response to substance |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
affects abundance |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
multiple interactions |
EXP |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
multiple interactions |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
multiple interactions |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
increases response to substance |
ISO |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SKIL |
SKI-like oncogene |
|
increases expression |
ISO |
3 |
170,075,473 |
170,114,637 |
RGD:6480464 |
CTD |
| G |
SLC12A1 |
solute carrier family 12 (sodium/potassium/chloride transporters), member 1 |
|
increases activity |
ISO |
15 |
48,498,498 |
48,596,275 |
RGD:6480464 |
CTD |
| G |
SLC12A1 |
solute carrier family 12 (sodium/potassium/chloride transporters), member 1 |
|
multiple interactions |
ISO |
15 |
48,498,498 |
48,596,275 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases stability |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases transport |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
ISO |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
decreases expression |
ISO |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases activity |
ISO |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases transport |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
increases expression |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
ISO |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
EXP |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
ISO |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
|
multiple interactions |
ISO |
1 |
43,391,046 |
43,424,847 |
RGD:6480464 |
CTD |
| G |
SLC2A11 |
solute carrier family 2 (facilitated glucose transporter), member 11 |
|
increases transport |
EXP |
22 |
24,199,059 |
24,227,738 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
multiple interactions |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
multiple interactions |
EXP |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
increases transport |
EXP |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
multiple interactions |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
increases expression |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
multiple interactions |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
increases expression |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
multiple interactions |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
|
increases expression |
ISO |
3 |
170,714,137 |
170,744,768 |
RGD:6480464 |
CTD |
| G |
SLC2A3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
|
multiple interactions |
EXP |
12 |
8,071,824 |
8,088,892 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
multiple interactions |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
increases expression |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
multiple interactions |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
multiple interactions |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
increases uptake |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
decreases expression |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
multiple interactions |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
increases uptake |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
|
increases uptake |
ISO |
17 |
7,185,054 |
7,191,367 |
RGD:6480464 |
CTD |
| G |
SLC2A5 |
solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
multiple interactions |
EXP |
1 |
9,097,005 |
9,129,887 |
RGD:6480464 |
CTD |
| G |
SLC2A5 |
solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
increases expression |
EXP |
1 |
9,097,005 |
9,129,887 |
RGD:6480464 |
CTD |
| G |
SLC2A5 |
solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
increases expression |
EXP |
1 |
9,097,005 |
9,129,887 |
RGD:6480464 |
CTD |
| G |
SLC2A5 |
solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
increases transport |
EXP |
1 |
9,097,005 |
9,129,887 |
RGD:6480464 |
CTD |
| G |
SLC2A5 |
solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
increases expression |
ISO |
1 |
9,097,005 |
9,129,887 |
RGD:6480464 |
CTD |
| G |
SLC2A5 |
solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
increases expression |
ISO |
1 |
9,097,005 |
9,129,887 |
RGD:6480464 |
CTD |
| G |
SLC2A5 |
solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
increases expression |
EXP |
1 |
9,097,005 |
9,129,887 |
RGD:6480464 |
CTD |
| G |
SLC2A6 |
solute carrier family 2 (facilitated glucose transporter), member 6 |
|
decreases expression |
ISO |
9 |
136,336,216 |
136,344,276 |
RGD:6480464 |
CTD |
| G |
SLC2A7 |
solute carrier family 2 (facilitated glucose transporter), member 7 |
|
increases transport |
EXP |
1 |
9,063,359 |
9,086,404 |
RGD:6480464 |
CTD |
| G |
SLC2A7 |
solute carrier family 2 (facilitated glucose transporter), member 7 |
|
increases transport |
EXP |
1 |
9,063,359 |
9,086,404 |
RGD:6480464 |
CTD |
| G |
SLC2A9 |
solute carrier family 2 (facilitated glucose transporter), member 9 |
|
multiple interactions |
EXP |
4 |
9,827,848 |
10,041,872 |
RGD:6480464 |
CTD |
| G |
SLC2A9 |
solute carrier family 2 (facilitated glucose transporter), member 9 |
|
increases transport |
EXP |
4 |
9,827,848 |
10,041,872 |
RGD:6480464 |
CTD |
| G |
SLC30A3 |
solute carrier family 30 (zinc transporter), member 3 |
|
multiple interactions |
ISO |
2 |
27,477,440 |
27,485,960 |
RGD:6480464 |
CTD |
| G |
SLC30A8 |
solute carrier family 30 (zinc transporter), member 8 |
|
multiple interactions |
ISO |
8 |
117,962,512 |
118,188,953 |
RGD:6480464 |
CTD |
| G |
SLC30A8 |
solute carrier family 30 (zinc transporter), member 8 |
|
multiple interactions |
ISO |
8 |
117,962,512 |
118,188,953 |
RGD:6480464 |
CTD |
| G |
SLC30A8 |
solute carrier family 30 (zinc transporter), member 8 |
|
multiple interactions |
EXP |
8 |
117,962,512 |
118,188,953 |
RGD:6480464 |
CTD |
| G |
SLC5A1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
|
affects transport |
EXP |
22 |
32,439,019 |
32,509,016 |
RGD:6480464 |
CTD |
| G |
SLC5A1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
|
increases expression |
ISO |
22 |
32,439,019 |
32,509,016 |
RGD:6480464 |
CTD |
| G |
SLC5A1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
|
multiple interactions |
ISO |
22 |
32,439,019 |
32,509,016 |
RGD:6480464 |
CTD |
| G |
SLC5A1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
|
multiple interactions |
EXP |
22 |
32,439,019 |
32,509,016 |
RGD:6480464 |
CTD |
| G |
SLC5A1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
|
increases expression |
ISO |
22 |
32,439,019 |
32,509,016 |
RGD:6480464 |
CTD |
| G |
SLC5A1 |
solute carrier family 5 (sodium/glucose cotransporter), member 1 |
|
multiple interactions |
ISO |
22 |
32,439,019 |
32,509,016 |
RGD:6480464 |
CTD |
| G |
SLC5A2 |
solute carrier family 5 (sodium/glucose cotransporter), member 2 |
|
multiple interactions |
ISO |
16 |
31,494,439 |
31,502,091 |
RGD:6480464 |
CTD |
| G |
SLC5A2 |
solute carrier family 5 (sodium/glucose cotransporter), member 2 |
|
multiple interactions |
ISO |
16 |
31,494,439 |
31,502,091 |
RGD:6480464 |
CTD |
| G |
SLC8A1 |
solute carrier family 8 (sodium/calcium exchanger), member 1 |
|
multiple interactions |
ISO |
2 |
40,339,286 |
40,739,575 |
RGD:6480464 |
CTD |
| G |
SLC8A1 |
solute carrier family 8 (sodium/calcium exchanger), member 1 |
|
multiple interactions |
ISO |
2 |
40,339,286 |
40,739,575 |
RGD:6480464 |
CTD |
| G |
SMAD2 |
SMAD family member 2 |
|
multiple interactions |
EXP |
18 |
45,359,466 |
45,457,517 |
RGD:6480464 |
CTD |
| G |
SMAD3 |
SMAD family member 3 |
|
multiple interactions |
EXP |
15 |
67,358,195 |
67,487,533 |
RGD:6480464 |
CTD |
| G |
SMC4 |
structural maintenance of chromosomes 4 |
|
increases expression |
ISO |
3 |
160,117,430 |
160,152,741 |
RGD:6480464 |
CTD |
| G |
SMOX |
spermine oxidase |
|
increases expression |
ISO |
20 |
4,129,426 |
4,168,394 |
RGD:6480464 |
CTD |
| G |
SOCS3 |
suppressor of cytokine signaling 3 |
|
increases expression |
ISO |
17 |
76,352,859 |
76,356,158 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
affects binding |
EXP |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
decreases expression |
ISO |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
affects folding |
EXP |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
decreases expression |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
decreases expression |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
ISO |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
decreases expression |
EXP |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
decreases response to substance |
EXP |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SOD3 |
superoxide dismutase 3, extracellular |
|
decreases expression |
ISO |
4 |
24,797,085 |
24,802,467 |
RGD:6480464 |
CTD |
| G |
SORD |
sorbitol dehydrogenase |
|
increases expression |
ISO |
15 |
45,315,302 |
45,367,287 |
RGD:6480464 |
CTD |
| G |
SP1 |
Sp1 transcription factor |
|
multiple interactions |
ISO |
12 |
53,773,979 |
53,810,230 |
RGD:6480464 |
CTD |
| G |
SP1 |
Sp1 transcription factor |
|
multiple interactions |
EXP |
12 |
53,773,979 |
53,810,230 |
RGD:6480464 |
CTD |
| G |
SPARC |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
decreases expression |
EXP |
5 |
151,040,657 |
151,066,615 |
RGD:6480464 |
CTD |
| G |
SPARC |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
multiple interactions |
EXP |
5 |
151,040,657 |
151,066,615 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
increases expression |
ISO |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
multiple interactions |
ISO |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
increases expression |
ISO |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
increases expression |
ISO |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
increases secretion |
ISO |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPRY2 |
sprouty homolog 2 (Drosophila) |
|
increases expression |
ISO |
13 |
80,910,111 |
80,915,086 |
RGD:6480464 |
CTD |
| G |
SPSB1 |
splA/ryanodine receptor domain and SOCS box containing 1 |
|
increases expression |
ISO |
1 |
9,352,941 |
9,429,591 |
RGD:6480464 |
CTD |
| G |
SRC |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
ISO |
20 |
35,973,088 |
36,033,821 |
RGD:6480464 |
CTD |
| G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
|
increases expression |
ISO |
17 |
17,714,663 |
17,740,325 |
RGD:6480464 |
CTD |
| G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
|
increases expression |
ISO |
17 |
17,714,663 |
17,740,325 |
RGD:6480464 |
CTD |
| G |
STAG2 |
stromal antigen 2 |
|
decreases expression |
ISO |
X |
123,094,475 |
123,236,506 |
RGD:6480464 |
CTD |
| G |
STAT1 |
signal transducer and activator of transcription 1, 91kDa |
|
multiple interactions |
ISO |
2 |
191,833,762 |
191,878,976 |
RGD:6480464 |
CTD |
| G |
STAT1 |
signal transducer and activator of transcription 1, 91kDa |
|
increases phosphorylation |
ISO |
2 |
191,833,762 |
191,878,976 |
RGD:6480464 |
CTD |
| G |
STRBP |
spermatid perinuclear RNA binding protein |
|
decreases expression |
ISO |
9 |
125,883,899 |
126,030,855 |
RGD:6480464 |
CTD |
| G |
SYVN1 |
synovial apoptosis inhibitor 1, synoviolin |
|
decreases expression |
ISO |
11 |
64,894,751 |
64,902,003 |
RGD:6480464 |
CTD |
| G |
TBX2 |
T-box 2 |
|
increases expression |
ISO |
17 |
59,477,257 |
59,486,827 |
RGD:6480464 |
CTD |
| G |
TGFA |
transforming growth factor, alpha |
|
multiple interactions |
EXP |
2 |
70,674,412 |
70,781,147 |
RGD:6480464 |
CTD |
| G |
TGFA |
transforming growth factor, alpha |
|
increases expression |
EXP |
2 |
70,674,412 |
70,781,147 |
RGD:6480464 |
CTD |
| G |
TGFA |
transforming growth factor, alpha |
|
multiple interactions |
ISO |
2 |
70,674,412 |
70,781,147 |
RGD:6480464 |
CTD |
| G |
TGFA |
transforming growth factor, alpha |
|
increases expression |
ISO |
2 |
70,674,412 |
70,781,147 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases secretion |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
increases expression |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
TGFB1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
19 |
41,836,812 |
41,859,831 |
RGD:6480464 |
CTD |
| G |
THG1L |
tRNA-histidine guanylyltransferase 1-like (S. cerevisiae) |
|
increases expression |
EXP |
5 |
157,158,323 |
157,166,772 |
RGD:6480464 |
CTD |
| G |
TLK1 |
tousled-like kinase 1 |
|
decreases expression |
ISO |
2 |
171,847,333 |
172,087,824 |
RGD:6480464 |
CTD |
| G |
TLR2 |
toll-like receptor 2 |
|
decreases expression |
EXP |
4 |
154,605,441 |
154,627,243 |
RGD:6480464 |
CTD |
| G |
TLR4 |
toll-like receptor 4 |
|
decreases expression |
EXP |
9 |
120,466,453 |
120,479,769 |
RGD:6480464 |
CTD |
| G |
TMED3 |
transmembrane emp24 protein transport domain containing 3 |
|
decreases expression |
ISO |
15 |
79,603,491 |
79,615,189 |
RGD:6480464 |
CTD |
| G |
TMSB4X |
thymosin beta 4, X-linked |
|
increases expression |
ISO |
X |
12,993,226 |
12,995,346 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
increases expression |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNFAIP6 |
tumor necrosis factor, alpha-induced protein 6 |
|
increases expression |
ISO |
2 |
152,214,106 |
152,236,562 |
RGD:6480464 |
CTD |
| G |
TNFRSF11B |
tumor necrosis factor receptor superfamily, member 11b |
|
multiple interactions |
EXP |
8 |
119,935,796 |
119,964,383 |
RGD:6480464 |
CTD |
| G |
TNFRSF11B |
tumor necrosis factor receptor superfamily, member 11b |
|
decreases secretion |
EXP |
8 |
119,935,796 |
119,964,383 |
RGD:6480464 |
CTD |
| G |
TNNT2 |
troponin T type 2 (cardiac) |
|
increases expression |
ISO |
1 |
201,328,142 |
201,346,805 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
multiple interactions |
EXP |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TRIB3 |
tribbles homolog 3 (Drosophila) |
|
multiple interactions |
ISO |
20 |
361,308 |
378,203 |
RGD:6480464 |
CTD |
| G |
TSC22D1 |
TSC22 domain family, member 1 |
|
increases expression |
ISO |
13 |
45,006,279 |
45,150,701 |
RGD:6480464 |
CTD |
| G |
TUBB2A |
tubulin, beta 2A class IIa |
|
increases expression |
ISO |
6 |
3,153,900 |
3,157,783 |
RGD:6480464 |
CTD |
| G |
TUBB6 |
tubulin, beta 6 class V |
|
increases expression |
ISO |
18 |
12,308,257 |
12,326,568 |
RGD:6480464 |
CTD |
| G |
TXN |
thioredoxin |
|
decreases expression |
ISO |
9 |
113,006,092 |
113,018,920 |
RGD:6480464 |
CTD |
| G |
TXN |
thioredoxin |
|
multiple interactions |
ISO |
9 |
113,006,092 |
113,018,920 |
RGD:6480464 |
CTD |
| G |
TXN |
thioredoxin |
|
decreases expression |
ISO |
9 |
113,006,092 |
113,018,920 |
RGD:6480464 |
CTD |
| G |
TXN |
thioredoxin |
|
decreases expression |
ISO |
9 |
113,006,092 |
113,018,920 |
RGD:6480464 |
CTD |
| G |
TXNIP |
thioredoxin interacting protein |
|
multiple interactions |
ISO |
1 |
145,438,462 |
145,442,635 |
RGD:6480464 |
CTD |
| G |
TXNIP |
thioredoxin interacting protein |
|
increases expression |
ISO |
1 |
145,438,462 |
145,442,635 |
RGD:6480464 |
CTD |
| G |
TXNIP |
thioredoxin interacting protein |
|
increases expression |
ISO |
1 |
145,438,462 |
145,442,635 |
RGD:6480464 |
CTD |
| G |
TXNIP |
thioredoxin interacting protein |
|
increases activity |
ISO |
1 |
145,438,462 |
145,442,635 |
RGD:6480464 |
CTD |
| G |
UCP1 |
uncoupling protein 1 (mitochondrial, proton carrier) |
|
decreases response to substance |
ISO |
4 |
141,481,050 |
141,489,959 |
RGD:6480464 |
CTD |
| G |
UCP1 |
uncoupling protein 1 (mitochondrial, proton carrier) |
|
multiple interactions |
ISO |
4 |
141,481,050 |
141,489,959 |
RGD:6480464 |
CTD |
| G |
UCP1 |
uncoupling protein 1 (mitochondrial, proton carrier) |
|
multiple interactions |
ISO |
4 |
141,481,050 |
141,489,959 |
RGD:6480464 |
CTD |
| G |
UCP2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
|
multiple interactions |
ISO |
11 |
73,685,716 |
73,693,889 |
RGD:6480464 |
CTD |
| G |
USF2 |
upstream transcription factor 2, c-fos interacting |
|
increases activity |
ISO |
19 |
35,759,896 |
35,770,718 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
increases expression |
EXP |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
increases expression |
EXP |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
EXP |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VCAM1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
EXP |
1 |
101,185,196 |
101,204,601 |
RGD:6480464 |
CTD |
| G |
VDR |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
multiple interactions |
ISO |
12 |
48,235,320 |
48,298,814 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
increases expression |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
increases expression |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
increases expression |
EXP |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
increases secretion |
EXP |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
VIMP |
VCP-interacting membrane protein |
|
affects expression |
ISO |
15 |
101,811,214 |
101,817,700 |
RGD:6480464 |
CTD |
| G |
WNT3A |
wingless-type MMTV integration site family, member 3A |
|
decreases expression |
ISO |
1 |
228,194,723 |
228,248,972 |
RGD:6480464 |
CTD |
| G |
WNT4 |
wingless-type MMTV integration site family, member 4 |
|
decreases expression |
ISO |
1 |
22,443,798 |
22,469,519 |
RGD:6480464 |
CTD |
| G |
WNT4 |
wingless-type MMTV integration site family, member 4 |
|
multiple interactions |
ISO |
1 |
22,443,798 |
22,469,519 |
RGD:6480464 |
CTD |
| G |
WNT5A |
wingless-type MMTV integration site family, member 5A |
|
decreases expression |
ISO |
3 |
55,499,743 |
55,521,670 |
RGD:6480464 |
CTD |
| G |
WNT5A |
wingless-type MMTV integration site family, member 5A |
|
multiple interactions |
ISO |
3 |
55,499,743 |
55,521,670 |
RGD:6480464 |
CTD |
| G |
WWP1 |
WW domain containing E3 ubiquitin protein ligase 1 |
|
decreases expression |
ISO |
8 |
87,354,994 |
87,480,181 |
RGD:6480464 |
CTD |
| G |
XBP1 |
X-box binding protein 1 |
|
decreases expression |
ISO |
22 |
29,190,548 |
29,196,560 |
RGD:6480464 |
CTD |
| G |
XBP1 |
X-box binding protein 1 |
|
increases expression |
ISO |
22 |
29,190,548 |
29,196,560 |
RGD:6480464 |
CTD |
| G |
XDH |
xanthine dehydrogenase |
|
multiple interactions |
ISO |
2 |
31,557,188 |
31,637,611 |
RGD:6480464 |
CTD |
| G |
ZNF519 |
zinc finger protein 519 |
|
decreases expression |
ISO |
18 |
14,075,989 |
14,132,489 |
RGD:6480464 |
CTD |
| G |
ZNF521 |
zinc finger protein 521 |
|
increases expression |
ISO |
18 |
22,641,888 |
22,932,214 |
RGD:6480464 |
CTD |
Term paths to the root
|